3-Deazaneplanocin A （DZNep）作为一个全新的靶向癌症表观遗传学过程的染色质修饰药物的鉴定与特性分析
摘要
癌症对于人类健康有巨大威胁并且是导致人类死亡的最常见的疾病之一。经过前一段时间里表观遗传学研究的快速发展,癌症现在已经被认为是无数遗传学和表观遗传学的变异在细胞内累计的最终结果。表观遗传修饰对于肿瘤形成和发展有主要的推动作用。所以靶向表观遗传修饰药物的研究受到人们高度重视。尽管我们已经掌握了这个理论,但是仍有一个问题需要被解答,那就是怎样将研究结果转换到临床的应用。最古老但也是最有效的方法就是使用化学化合物来实现这个目标。本研究中我确认了一个崭新的作用于表观遗传调控的化合物3-Deazaneplanocin A(DZNep),并且将其应用于多种肿瘤细胞后发现了DZNep诱导凋亡的能力和它的作用机制。DZNep可以靶向PRC2蛋白,我们使用DZNep作为工具发现一些重要的PRC2靶基因,并且确认他们在肿瘤生物学中的功能。我也选择一个已知的肿瘤抑制基因CDKN1C来加以研究,详细分析其转录起始位点的表观遗传修饰模式。并且这个EZH2靶基因在乳腺癌患者中有强的预后价值。
1.筛选化合物库后发现3-Deazaneplanocin A(DZNep)并确认其诱导肿瘤细胞E2F1依赖凋亡的活性
肿瘤的发生取决于细胞生长和程序死亡是否能保持精确平衡。Rb/E2F1通路在调控细胞周期中起到重要作用。已经有报道发现表观遗传抗肿瘤药物SAHA能通过激活E2F1下游靶基因Bim诱导肿瘤特异的凋亡。这里我展开大规模药物筛选以发现更多的类似SAHA可以通过E2F1通路诱导凋亡的药物。我用基于HCT 116 p53 null ER-E2F1细胞株的筛选平台筛选了一个包括了4000个化合物National Cancer Institute(NCI)化合物库。经过不同方法和细胞系的筛选和确认,我发现一个活性化合物3-Deazaneplanocin A(DZNep)。DZNep诱导E2F1依赖凋亡的能力通过检测不同凋亡标志被确认。DZNep可以促进E2F1促凋亡的靶基因表达,这些高度表达的基因最终导致细胞凋亡。
2通过药理学方法抑制Polycomb-repressive complex 2介导的基因抑制可选择性诱导肿瘤细胞凋亡
Polycomb-repressive complex 2(PRC2)介导的组蛋白甲基化在肿瘤基因异常沉默中起到重点作用,并且成为癌症治疗的潜在靶点。这里我发现S-adenosylhomocysteine水解酶抑制剂3-Deazaneplanocin A(DZNep)有效诱导肿瘤细胞凋亡但对正常细胞没有作用。我发现DZNep有效消除细胞内PRC2组分包括EZH2,SUZ12和EED蛋白并且抑制相关的组蛋白H3赖氨酸27位三甲基化(但不是组蛋白H3赖氨酸9位三甲基化)。通过RNA干扰分析,全基因组表达分析和染色质免疫沉淀研究,我确认一组突出的基因在乳腺肿瘤中被PRC2抑制,并且它们的表达可被DZNep重新激活。我进一步展示DZNep优先的激活包括新发现的凋亡作用子FBXO32的一系列基因,都对DZNep诱导的乳腺肿瘤细胞凋亡起作用。我的结果显示DZNep作为崭新的改变染色质的化合物具有独一无二的特点,并且提出了通过药理学DZNep处理来逆转PRC2介导的基因抑制将可能是一种崭新的治疗肿瘤的方法。
3.肿瘤抑制基因CDKN1C(p57KIP2)是EZH2靶标并且在乳腺肿瘤中通过不同组蛋白修饰协同作用而被抑制
CDKN1C(编码p57~(KIP2))是周期素依赖性激酶(CDK)抑制剂肿瘤抑制家族中的一员,它在人类肿瘤通常通过启动子区域的DNA甲基化而被抑制。在这一部分工作中我发现CDKN1C在乳腺肿瘤细胞中的抑制与DNA甲基化状态无关。我证明CDKN1C转录通过Polycomb蛋白EZH2及其相关组蛋白赖氨酸27位甲基化而抑制。用S-adenosylhomocysteine水解酶抑制剂3-Deazaneplanosin A(DZNep)处理导致EZH2蛋白表达和H3K27me3的抑制,如果联合使用组蛋白去乙酰酶抑制剂Trichostatin A(TSA)来有效逆转组蛋白修饰将导致一个CDKN1C表达的惊人升高。单独消除EZH2并不足以激活CDKN1C但是加入TSA就可以达到这个目的。这就显示了组蛋白甲基化和去乙酰化协同而抑制CDKN1C表达。进一步研究显示CDKN1C表达抑制在包括乳腺肿瘤的多种人类肿瘤中存在。并且联合高EZH2和低CDKN1C表达水平可以预测一个乳腺肿瘤的特别不良预后。总的来说这些发现揭示在乳腺肿瘤中CDKN1C表达抑制的一个崭新的机制,并且发现其作为EZH2靶点的预后价值。我在这里要特别指出了一个在乳腺肿瘤中通过药理学途径重新激活CDKN1C肿瘤抑制基因的有效方法。
Cancer is a great threat to human health and is one of the most lethiferous diseases.With the fast growing epigenetic research during last decade,cancer now is known as a phenotypic end point of numerous genetics and/or epigenetic alternation that have accumulated within cells.It is clear that epigenetic modifications are major contributors for formation and progression of tumor,so targeting epigenetic modifications has been put under the spotlight of investigation.Although having this principle in hand,there is one question has to be addressed that is how to translate research paper to clinic benefit. The eldest but still most efficient way is using chemical compound to achieve this aim.In this study I identified a novel compound 3-Deazaneplanocin A(DZNep) affecting epigenetic regulation and applied it in multiple cancer cells to point out its working mechanism.With the exciting finding that DZNep target PcG proteins,we use DZNep as a tool to fish out some important PcG target genes and identify their function in cancer biology.We also pick up one well known tumor suppressor CDKN1C and detailed characterized the epigenetic modification pattern around its transcription start site.And this EZH2 target gene show strong prognosis value in breast cancer patients.
1.Screening compound library and identifying 3-Deazaneplanocin A (DZNep) can induce cell apoptosis in a E2F1 depend manner
The development of cancer depends on delicate balance between cell proliferation and programmed cell death.Rb/E2F1 pathway plays an important role in regulation cell cycle. It has been reported that epigenetic anticancer drug SAHA can induce cancer specific apoptosis through activating E2F1 downstream target Bim.Here I carry out a drug screen to search more SAHA-like compounds which can induce apoptosis through E2F1 pathway.A National Cancer Institute(NCI) compound library including around 4000 compounds was submitted to the established screen platform based on HCT 116 p53 null ER-E2F1 cell line.After screen and validation through different method and cell line system,I have identified one compound named 3-Deazaneplanocin A(DZNep).The ability of DZNep to induce E2F1-dependent apoptosis is confirmed through analyzing different apoptosis markers.DZNep can promote E2F1 pro-apoptosis target genes expression and these highly active genes led to apoptosis.
2.Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Polycomb-repressive complex 2(PRC2)-mediated histone methylation plays an important role in aberrant cancer gene silencing and is a potential target for cancer therapy.Here we show that S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A(DZNep) induces efficient apoptotic cell death in cancer cells but not in normal cells.We found that DZNep effectively depleted cellular levels of PRC2 components EZH2,SUZ12 and EED while also inhibited associated histone H3 Lys 27 methylation(but not H3 Lys 9 methylation).By integrating RNA interference(RNAi), genome-wide expression analysis,and chromatin immunoprecipitation(CHIP) studies,we have identified a prominent set of genes selectively repressed by PRC2 in breast cancer that can be reactivated by DZNep.We further demonstrate that the preferential reactivation of a set of these genes by DZNep,including a novel apoptosis affector, FBXO32,contributes to DZNep-induced apoptosis in breast cancer cells.Our results demonstrate the unique feature of DZNep as a novel chromatin remodeling compound and suggest that pharmacologic reversal of PRC2-mediated gene repression by DZNep may constitute a novel approach for cancer therapy.
3.Tumor Suppressor CDKN1C(p57~(KIP2)) is an EZH2 target and transcriptionally repressed in breast cancer cells through coordinated action of histone modifications
CDKN1C(encoding p57~(KIP2)) is a member of cyclin-dependent kinase(CDK) inhibitor tumor suppressor family that is often transcriptionally inactivated in human cancer via promoter DNA methylation.In this study,we show that CDKN1C repression in breast cancer cells is not associated with the status of DNA methylation.We demonstrate that CDKN1C transcription is repressed by Polycomb protein EZH2 and associated histone H3 lysine 27 trimethylation(H3K27me3).Treatment of breast cancer cells with Sadenosylhomocysteine hydrolase inhibitor 3-Deazaneplanosin A(DZNep) which inhibits EZH2 protein expression and H3K27me3,together with histone deacetylase inhibitor Trichostatin A(TSA) caused a robust induction of CDKN1C expression through effective reversal of histone modifications.Depletion of EZH2 alone is insufficient to activate CDKN1C but does so in the presence of TSA,suggesting that histone methylation and deacetylation coordinate to repress CDKN1C expression.We further show that CDKN1C expression is underexpressed in multiple human cancers including breast cancer,and the combination of high EZH2 and low CDKN1C expression predicts an extreme poor prognosis of breast cancer.Taken together,these findings reveal a novel mechanism underlying CDKN1C repression in breast cancer and its prognostic value as an EZH2 target.In particular we point out an effective approach for pharmacological reactivation of CDKN1C tumor suppressor in breast cancer.
1.筛选化合物库后发现3-Deazaneplanocin A(DZNep)并确认其诱导肿瘤细胞E2F1依赖凋亡的活性
肿瘤的发生取决于细胞生长和程序死亡是否能保持精确平衡。Rb/E2F1通路在调控细胞周期中起到重要作用。已经有报道发现表观遗传抗肿瘤药物SAHA能通过激活E2F1下游靶基因Bim诱导肿瘤特异的凋亡。这里我展开大规模药物筛选以发现更多的类似SAHA可以通过E2F1通路诱导凋亡的药物。我用基于HCT 116 p53 null ER-E2F1细胞株的筛选平台筛选了一个包括了4000个化合物National Cancer Institute(NCI)化合物库。经过不同方法和细胞系的筛选和确认,我发现一个活性化合物3-Deazaneplanocin A(DZNep)。DZNep诱导E2F1依赖凋亡的能力通过检测不同凋亡标志被确认。DZNep可以促进E2F1促凋亡的靶基因表达,这些高度表达的基因最终导致细胞凋亡。
2通过药理学方法抑制Polycomb-repressive complex 2介导的基因抑制可选择性诱导肿瘤细胞凋亡
Polycomb-repressive complex 2(PRC2)介导的组蛋白甲基化在肿瘤基因异常沉默中起到重点作用,并且成为癌症治疗的潜在靶点。这里我发现S-adenosylhomocysteine水解酶抑制剂3-Deazaneplanocin A(DZNep)有效诱导肿瘤细胞凋亡但对正常细胞没有作用。我发现DZNep有效消除细胞内PRC2组分包括EZH2,SUZ12和EED蛋白并且抑制相关的组蛋白H3赖氨酸27位三甲基化(但不是组蛋白H3赖氨酸9位三甲基化)。通过RNA干扰分析,全基因组表达分析和染色质免疫沉淀研究,我确认一组突出的基因在乳腺肿瘤中被PRC2抑制,并且它们的表达可被DZNep重新激活。我进一步展示DZNep优先的激活包括新发现的凋亡作用子FBXO32的一系列基因,都对DZNep诱导的乳腺肿瘤细胞凋亡起作用。我的结果显示DZNep作为崭新的改变染色质的化合物具有独一无二的特点,并且提出了通过药理学DZNep处理来逆转PRC2介导的基因抑制将可能是一种崭新的治疗肿瘤的方法。
3.肿瘤抑制基因CDKN1C(p57KIP2)是EZH2靶标并且在乳腺肿瘤中通过不同组蛋白修饰协同作用而被抑制
CDKN1C(编码p57~(KIP2))是周期素依赖性激酶(CDK)抑制剂肿瘤抑制家族中的一员,它在人类肿瘤通常通过启动子区域的DNA甲基化而被抑制。在这一部分工作中我发现CDKN1C在乳腺肿瘤细胞中的抑制与DNA甲基化状态无关。我证明CDKN1C转录通过Polycomb蛋白EZH2及其相关组蛋白赖氨酸27位甲基化而抑制。用S-adenosylhomocysteine水解酶抑制剂3-Deazaneplanosin A(DZNep)处理导致EZH2蛋白表达和H3K27me3的抑制,如果联合使用组蛋白去乙酰酶抑制剂Trichostatin A(TSA)来有效逆转组蛋白修饰将导致一个CDKN1C表达的惊人升高。单独消除EZH2并不足以激活CDKN1C但是加入TSA就可以达到这个目的。这就显示了组蛋白甲基化和去乙酰化协同而抑制CDKN1C表达。进一步研究显示CDKN1C表达抑制在包括乳腺肿瘤的多种人类肿瘤中存在。并且联合高EZH2和低CDKN1C表达水平可以预测一个乳腺肿瘤的特别不良预后。总的来说这些发现揭示在乳腺肿瘤中CDKN1C表达抑制的一个崭新的机制,并且发现其作为EZH2靶点的预后价值。我在这里要特别指出了一个在乳腺肿瘤中通过药理学途径重新激活CDKN1C肿瘤抑制基因的有效方法。
Cancer is a great threat to human health and is one of the most lethiferous diseases.With the fast growing epigenetic research during last decade,cancer now is known as a phenotypic end point of numerous genetics and/or epigenetic alternation that have accumulated within cells.It is clear that epigenetic modifications are major contributors for formation and progression of tumor,so targeting epigenetic modifications has been put under the spotlight of investigation.Although having this principle in hand,there is one question has to be addressed that is how to translate research paper to clinic benefit. The eldest but still most efficient way is using chemical compound to achieve this aim.In this study I identified a novel compound 3-Deazaneplanocin A(DZNep) affecting epigenetic regulation and applied it in multiple cancer cells to point out its working mechanism.With the exciting finding that DZNep target PcG proteins,we use DZNep as a tool to fish out some important PcG target genes and identify their function in cancer biology.We also pick up one well known tumor suppressor CDKN1C and detailed characterized the epigenetic modification pattern around its transcription start site.And this EZH2 target gene show strong prognosis value in breast cancer patients.
1.Screening compound library and identifying 3-Deazaneplanocin A (DZNep) can induce cell apoptosis in a E2F1 depend manner
The development of cancer depends on delicate balance between cell proliferation and programmed cell death.Rb/E2F1 pathway plays an important role in regulation cell cycle. It has been reported that epigenetic anticancer drug SAHA can induce cancer specific apoptosis through activating E2F1 downstream target Bim.Here I carry out a drug screen to search more SAHA-like compounds which can induce apoptosis through E2F1 pathway.A National Cancer Institute(NCI) compound library including around 4000 compounds was submitted to the established screen platform based on HCT 116 p53 null ER-E2F1 cell line.After screen and validation through different method and cell line system,I have identified one compound named 3-Deazaneplanocin A(DZNep).The ability of DZNep to induce E2F1-dependent apoptosis is confirmed through analyzing different apoptosis markers.DZNep can promote E2F1 pro-apoptosis target genes expression and these highly active genes led to apoptosis.
2.Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Polycomb-repressive complex 2(PRC2)-mediated histone methylation plays an important role in aberrant cancer gene silencing and is a potential target for cancer therapy.Here we show that S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A(DZNep) induces efficient apoptotic cell death in cancer cells but not in normal cells.We found that DZNep effectively depleted cellular levels of PRC2 components EZH2,SUZ12 and EED while also inhibited associated histone H3 Lys 27 methylation(but not H3 Lys 9 methylation).By integrating RNA interference(RNAi), genome-wide expression analysis,and chromatin immunoprecipitation(CHIP) studies,we have identified a prominent set of genes selectively repressed by PRC2 in breast cancer that can be reactivated by DZNep.We further demonstrate that the preferential reactivation of a set of these genes by DZNep,including a novel apoptosis affector, FBXO32,contributes to DZNep-induced apoptosis in breast cancer cells.Our results demonstrate the unique feature of DZNep as a novel chromatin remodeling compound and suggest that pharmacologic reversal of PRC2-mediated gene repression by DZNep may constitute a novel approach for cancer therapy.
3.Tumor Suppressor CDKN1C(p57~(KIP2)) is an EZH2 target and transcriptionally repressed in breast cancer cells through coordinated action of histone modifications
CDKN1C(encoding p57~(KIP2)) is a member of cyclin-dependent kinase(CDK) inhibitor tumor suppressor family that is often transcriptionally inactivated in human cancer via promoter DNA methylation.In this study,we show that CDKN1C repression in breast cancer cells is not associated with the status of DNA methylation.We demonstrate that CDKN1C transcription is repressed by Polycomb protein EZH2 and associated histone H3 lysine 27 trimethylation(H3K27me3).Treatment of breast cancer cells with Sadenosylhomocysteine hydrolase inhibitor 3-Deazaneplanosin A(DZNep) which inhibits EZH2 protein expression and H3K27me3,together with histone deacetylase inhibitor Trichostatin A(TSA) caused a robust induction of CDKN1C expression through effective reversal of histone modifications.Depletion of EZH2 alone is insufficient to activate CDKN1C but does so in the presence of TSA,suggesting that histone methylation and deacetylation coordinate to repress CDKN1C expression.We further show that CDKN1C expression is underexpressed in multiple human cancers including breast cancer,and the combination of high EZH2 and low CDKN1C expression predicts an extreme poor prognosis of breast cancer.Taken together,these findings reveal a novel mechanism underlying CDKN1C repression in breast cancer and its prognostic value as an EZH2 target.In particular we point out an effective approach for pharmacological reactivation of CDKN1C tumor suppressor in breast cancer.
引文
Bates,S.,A.C.Phillips,et al.(1998)."p14ARF links the tumour suppressors RB and p53." Nature 395(6698):124-5.
Bieda,M.,X.Xu,et al.(2006)."Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome." Genome Res 16(5):595-605.
Boutillier,A.L.,E.Trinh,et al.(2003)."Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis." J Neurochem 84(4):814-28.
Bracken,A.P.,D.Pasini,et al.(2003)."EZH2 is downstream of the pRB-E2F pathway,essential for proliferation and amplified in cancer." Embo J 22(20):5323-35.
Brooks,W.H.,D.E.McCloskey,et al.(2007)."In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase." J Chem Inf Model 47(5):1897-905.
Cam,H.and B.D.Dynlacht(2003)."Emerging roles for E2F:beyond the G1/S transition and DNA replication." Cancer Cell 3(4):311-6.
Chiang,P.K.,P.D.Burbelo,et al.(1992)."Activation of collagen Ⅳ gene expression in F9 teratocarcinoma cells by 3-deazaadenosine analogs.Indirect inhibitors of methylation." J Biol Chem 267(7):4988-91.
Chiang,P.K.and G.L.Cantoni(1979)."Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo." Biochem Pharmacol 28(12):1897-902.
Chuikov,S.,J.K.Kurash,et al.(2004)."Regulation of p53 activity through lysine methylation." Nature 432(7015):353-60.
Dyson,N.(1998)."The regulation of E2F by pRB-family proteins." Genes Dev 12(15):2245-62.
Field,S.J.,F.Y.Tsai,et al.(1996)."E2F-1 functions in mice to promote apoptosis and suppress proliferation." Cell 85(4):549-61.
Fortin,A.,J.G.MacLaurin,et al.(2004)."The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1." J Biol Chem 279(27):28706-14.
Furukawa,Y.,N.Nishimura,et al.(2002)."Apaf-1 is a mediator of E2F-1-induced apoptosis." J Biol Chem 277(42):39760-8.
Gasparetto,M.,T.Gentry,et al.(2004)."Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow eytometric high-content screening." J Immunol Methods 292(1-2):59-71.
Glazer,R.I.,M.C.Knode,et al.(1986)."3-Deazaneplanocin A:a new inhibitor of Sadenosylhomocysteine synthesis and its effects in human colon carcinoma cells."Biochem Pharmacol 35(24):4523-7.
Hall,M.and G.Peters(1996)."Genetic alterations of cyclins,cyclin-dependent kinases,and Cdk inhibitors in human cancer." Adv Cancer Res 68:67-108.
Hao,H.,Y.Dong,et al.(2007)."E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation." BMC Cancer 7:24.
Hershko,T.and D.Ginsberg(2004)."Up-regulation of Bcl-2 homology 3(BH3)-only proteins by E2F1 mediates apoptosis." J Biol Chem 279(10):8627-34.
Holbeck,S.L.(2004)."Update on NCI in vitro drug screen utilities." Eur J Cancer 40(6):785-93.
Huang,C.L.,D.Liu,et al.(2007)."E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer." Clin Cancer Res 13(23):6938-46.
Irwin,M.,M.C.Marin,et al.(2000)."Role for the p53 homologue p73 in E2F-1-induced apoptosis." Nature 407(6804):645-8.
Johnson,D.G.and J.Degregori(2006)."Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context." Curr Mol Med 6(7):731-8.
Kraker,A.J.,C.A.Mizzen,et al.(2003)."Modulation ofhistone acetylation by[4-(acetylamino)-N-(2-amino-phenyl)benzamide]in HCT-8 colon carcinoma." Mol Cancer Ther 2(4):401-8.
Lowe,S.W.,E.Cepero,et al.(2004)."Intrinsic tumour suppression." Nature 432(7015):307-15.
Lu,Z.,R.Z.Luo,et al.(2006)."E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer." Oncogene 25(2):230-9.
Moroni,M.C.,E.S.Hickman,et al.(2001)."Apaf-1 is a transcriptional target for E2F and p53." Nat Cell Biol 3(6):552-8.
Mundle,S.D.and G.Saberwal(2003)."Evolving intricacies and implications of E2F1regulation." Faseb J 17(6):569-74.
Nahle,Z.,J.Polakoff,et al.(2002)."Direct coupling of the cell cycle and cell death machinery by E2F." Nat Cell Biol 4(11):859-64.
Pediconi,N.,A.Ianari,et al.(2003)."Differential regulation of E2F1 apoptotic target genes in response to DNA damage." Nat Cell Biol 5(6):552-8.
Powers,J.T.,S.Hong,et al.(2004)."E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis." Mol Cancer Res 2(4):203-14.
Rayman,J.B.,Y.Takahashi,et al.(2002)."E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex." Genes Dev 16(8):933-47.
Real,P.J.,C.Sanz,et al.(2006)."Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells." FEBS Lett 580(25):5905-9.
Robertson,K.D.,S.Ait-Si-Ali,et al.(2000)."DNMT1 forms a complex with Rb,E2F1and HDAC1 and represses transcription from E2F-responsive promoters." Nat Genet 25(3):338-42.
Rogoff,H.A.,M.T.Picketing,et al.(2002)."E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis." Mol Cell Biol 22(15):5308-18.
Rogoff,H.A.,M.T.Picketing,et al.(2004)."Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbsl/Chk2." Mol Cell Biol 24(7):2968-77.
Sherr,C.J.(1996)."Cancer cell cycles." Science 274(5293):1672-7.
Stiewe,T.and B.M.Putzer(2000)."Role of the p53-homologue p73 in E2F1-induced apoptosis." Nat Genet 26(4):464-9.
Tan,J.,L.Zhuang,et al.(2006)."Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity." J Biol Chem 281(15):10508-15.
Trimarchi,J.M.and J.A.Lees(2002)."Sibling rivalry in the E2F family." Nat Rev Mol Cell Biol 3(1):11-20.
Tyagi,S.,A.L.Chabes,et al.(2007)."E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4methyltransferases." Mol Cell 27(1):107-19.
Xiao,Q.,L.Li,et al.(2007)."Transcription factor E2F-1 is upregulated in human gastric cancer tissues and its overexpression suppresses gastric tumor cell proliferation."Cell Oncol 29(4):335-49.
Xie,W.,P.Jiang,et al.(2006)."Novel link between E2F1 and Smac/DIABLO:proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1." Nucleic Acids Res 34(7):2046-55.
Yamasaki,L.,T.Jacks,et al.(1996)."Tumor induction and tissue atrophy in mice lacking E2F-1." Cell 85(4):537-48.
Zhao,Y.,J.Tan,et al.(2005)."Inhibitors ofhistone deacetylases target the Rb-E2F1pathway for apoptosis induction through activation ofproapoptotic protein Bim."Proc Natl Acad Sci U S A 102(44):16090-5.
Zhu,J.W.,D.DeRyckere,et al.(1999)."A role for E2F1 in the induction of ARF,p53,and apoptosis during thymic negative selection." Cell Growth Differ 10(12):829-38.
Zhu,W.,P.H.Giangrande,et al.(2004)."E2Fs link the control of G1/S and G2/M transcription." Embo J 23(23):4615-26.
Allred,D.C.,S.K.Mohsin,et al.(2001)."Histological and biological evolution of human premalignant breast disease." Endocr Relat Cancer 8(1):47-61.
Beisel,C.,A.Imhof,et al.(2002)."Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1." Nature 419(6909):857-62.
Bemstein,B.E.,T.S.Mikkelsen,et al.(2006)."A bivalent chromatin structure marks key developmental genes in embryonic stem cells." Cell 125(2):315-26.
Boyer,L.A.,K.Plath,et al.(2006)."Polycomb complexes repress developmental regulators in murine embryonic stem cells." Nature.
Bracken,A.P.,N.Dietrich,et al.(2006)."Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions." Genes Dev 20(9):1123-36.
Bracken,A.P.,D.Pasini,et al.(2003)."EZH2 is downstream of the pRB-E2F pathway,essential for proliferation and amplified in cancer." Embo J 22(20):5323-35.
Bray,M.,J.Driscoll,et al.(2000)."Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor."Antiviral Res 45(2):135-47.
Burstein,H.J.,K.Polyak,et al.(2004)."Ductal carcinoma in situ of the breast." N Engl J Med 350(14):1430-41.
Cao,R.,L.Wang,et al.(2002)."Role of histone H3 lysine 27 methylation in Polycomb-group silencing." Science 298(5595):1039-43.
Cao,R.and Y.Zhang(2004)."SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex." Mol Cell 15(1):57-67.
Cheema,B.,C.A.Gaul,et al.(2007)."Progressive resistance training in breast cancer:a systematic review of clinical trials." Breast Cancer Res Treat.
Cheng,J.C.,C.B.Yoo,et al.(2004)."Preferential response of cancer cells to zebularine." Cancer Cell 6(2):151-8.
De Clercq,E.,M.Cools,et al.(1989)."Broad-spectrum antiviral activities of neplanocin A,3-deazaneplanocin A,and their 5'-nor derivatives." Antimicrob Agents Chemother 33(8):1291-7.
Ehrich,M.,M.R.Nelson,et al.(2005)."Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry." Proc Natl Acad Sci U S A 102(44):15785-90.
Fucito,A.,C.Lucchetti,et al.(2007)."Genetic and epigenetic alterations in breast cancer:What are the perspectives for clinical practice?" Int J Biochem Cell Biol.
Fujii,Y.,M.Yada,et al.(2006)."Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation." Cancer Sci 97(8):729-36.
Gil,J.,D.Bernard,et al.(2005)."Role of polycomb group proteins in stem cell self-renewal and cancer." DNA Cell Biol 24(2):117-25.
Glazer,R.I.,K.D.Hartman,et al.(1986)."3-Deazaneplanocin:a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60." Biochem Biophys Res Commun 135(2):688-94.
Haupt,Y.,W.S.Alexander,et al.(1991)."Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice." Cell 65(5):753-63.
Holden,C.(2006)."Development.Gene-suppressing proteins reveal secrets of stem cells." Science 312(5772):349.
Huh,J.I.,A.Calvo,et al.(2005)."Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms." Oncogene 24(5):790-800.
Imai,K.and A.Takaoka(2006)."Comparing antibody and small-molecule therapies for cancer." Nat Rev Cancer 6(9):714-27.
Jones,P.A.and S.B.Baylin(2007)."The epigenomics of cancer." Cell 128(4):683-92.
Kalantry,S.,K.C.Mills,et al.(2006)."The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation." Nat Cell Biol 8(2):195-202.
Kamangar,F.,G.M.Dores,et al.(2006)."Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world." J Clin Oncol 24(14):2137-50.
Kamminga,L.M.,L.V.Bystrykh,et al.(2006)."The Polycomb group gene Ezh2prevents hematopoietic stem cell exhaustion." Blood 107(5):2170-9.
Kennison,J.A.(1995)."The Polycomb and trithorax group proteins of Drosophila:transregulators of homeotic gene function." Annu Rev Genet 29:289-303.
Kirmizis,A.,S.M.Bartley,et al.(2003)."Identification of the polycomb group protein SU(Z) 12 as a potential molecular target for human cancer therapy." Mol Cancer Ther 2(1):113-21.
Kirmizis,A.,S.M.Bartley,et al.(2004)."Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27." Genes Dev 18(13):1592-605.
Kleer,C.G.,Q.Cao,et al.(2003)."EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells." Proc Natl Acad Sci U S A 100(20):11606-11.
Kuzmichev,A.,R.Margueron,et al.(2005)."Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation."Proc Natl Acad Sci U S A 102(6):1859-64.
Lee,T.I.,R.G.Jenner,et al.(2006)."Control of developmental regulators by Polycomb in human embryonic stem cells." Cell 125(2):301-13.
Lehnertz,B.,Y.Ueda,et al.(2003)."Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin." Curr Biol 13(14):1192-200.
Levine,S.S.,I.F.King,et al.(2004)."Division of labor in polycomb group repression."Trends Biochem Sci 29(9):478-85.
Lin,D.I.,O.Barbash,et al.(2006)."Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystaUin) complex." Mol Cell 24(3):355-66.
Lund,A.H.and M.van Lohuizen(2004)."Polycomb complexes and silencing mechanisms." Curr Opin Cell Biol 16(3):239-46.
Milne,T.A.,S.D.Briggs,et al.(2002)."MLL targets SET domain methyltransferase activity to Hox gene promoters." Mol Cell 10(5):1107-17.
Minella,A.C.and B.E.Clurman(2005)."Mechanisms of tumor suppression by the SCF(Fbw7)." Cell Cycle 4(10):1356-9.
Montgomery,N.D.,D.Yee,et al.(2005)."The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation." Curr Biol 15(10):942-7.
Muller,J.,C.M.Hart,et al.(2002)."Histone methyltransferase activity of a Drosophila Polycomb group repressor complex." Cell 111(2):197-208.
Nakamura,T.,T.Mori,et al.(2002)."ALL-1 is a historic methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation." Mol Cell 10(5):1119-28.
Pan,G.(2007)."Whole-Genome Analysis of Histone H3 Lysine 4 and Lysine 27Methylation in Human Embryonic Stem Cells." Cell Stem Cell 1:299-312.
Pasini,D.,A.P.Bracken,et al.(2004)."Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity." Embo J 23(20):4061-71.
Perou,C.M.,T.Sorlie,et al.(2000)."Molecular portraits of human breast tumours."Nature 406(6797):747-52.
Peters,A.H.,D.O'Carroll,et al.(2001)."Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability." Cell 107(3):323-37.
Pirrotta,V.(2006)."Polycomb silencing mechanisms and genomic programming." Ernst Schering Res Found Workshop(57):97-113.
Polyak,K.(2007)."Breast cancer:origins and evolution." J Clin Invest 117(11):3155-63.
Rea,S.,F.Eisenhaber,et al.(2000)."Regulation of chromatin structure by site-specific histone H3 methyltransferases." Nature 406(6796):593-9.
Rennert,G.,S.Bisland-Naggan,et al.(2007)."Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations." N Engl J Med 357(2):115-23.
Rhodes,D.R.,M.G.Sanda,et al.(2003)."Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer." J Natl Cancer Inst 95(9):661-8.
Schlesinger,Y.,R.Straussman,et al.(2007)."Polycomb-mediated methylation on Lys27of histone H3 pre-marks genes for de novo methylation in cancer." Nat Genet 39(2):232-6.
Sellers,W.R.and M.Loda(2002)."The EZH2 polycomb transcriptional repressor—a marker or mover of metastatic prostate cancer?" Cancer Cell 2(5):349-50.
Sorlie,T.,C.M.Perou,et al.(2001)."Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications." Proc Natl Acad Sci U S A 98(19):10869-74.
Sparmann,A.and M.van Lohuizen(2006)."Polycomb silencers control cell fate,development and cancer." Nat Rev Cancer 6(11):846-56.
Stitt,T.N.,D.Drujan,et al.(2004)."The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors." Mol Cell 14(3):395-403.
Tseng,C.K.,V.E.Marquez,et al.(1989)."Synthesis of 3-deazaneplanocin A,a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities." J Med Chem 32(7):1442-6.
Varambally,S.,S.M.Dhanasekaran,et al.(2002)."The polycomb group protein EZH2 is involved in progression of prostate cancer." Nature 419(6907):624-9.
Vargo-Gogola,T.and J.M.Rosen(2007)."Modelling breast cancer:one size does not fit all." Nat Rev Cancer 7(9):659-72.
Velicescu,M.,D.J.Weisenberger,et al.(2002)."Cell division is required for de novo methylation of CpG islands in bladder cancer cells." Cancer Res 62(8):2378-84.
Vire,E.,C.Brenner,et al.(2006)."The Polycomb group protein EZH2 directly controls DNA methylation." Nature 439(7078):871-4.
Welcker,M.,A.Orian,et al.(2004)."The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation." Proc Natl Acad Sci U S A 101(24):9085-90.
Widakowich,C.,E.de Azambuja,et al.(2007)."Molecular targeted therapies in breast cancer:where are we now?" Int J Biochem Cell Biol 39(7-8):1375-87.
Azuara,V.,P.Perry,et al.(2006)."Chromatin signatures of pluripotent cell lines." Nat Cell Biol 8(5):532-8.
Bachmann,I.M.,O.J.Halvorsen,et al.(2006)."EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium,prostate,and breast." J Clin Oncol 24(2):268-73.
Bernstein,B.E.,T.S.Mikkelsen,et al.(2006)."A bivalent chromatin structure marks key developmental genes in embryonic stem cells." Cell 125(2):315-26.
Chim,C.S.,T.K.Fung,et al.(2003)."Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS." Leukemia 17(12):2533-5.
Egger,G.,A.M.Aparicio,et al.(2007)."Inhibition of histone deacetylation does not block resilencing of p 16 after 5-aza-2'-deoxycytidine treatment." Cancer Res 67(1):346-53.
Elmore,J.G.,M.B.Barton,et al.(1998)."Ten-year risk of false positive screening mammograms and clinical breast examinations." N Engl J Med 338(16):1089-96.
Fahraeus,R.and D.P.Lane(1999)."The p 16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts." Embo J 18(8):2106-18.
Franklin,D.S.,V.L.Godfrey,et al.(1998)."CDK inhibitors p18(INK4c) and p27(Kip1)mediate two separate pathways to collaboratively suppress pituitary tumorigenesis." Genes Dev 12(18):2899-911.
Gamboa-Dominguez,A.,S.Seidl,et al.(2007)."Prognostic significance of p21WAF1/CIP1,p27Kip1,p53 and E-cadherin expression in gastric cancer." J Clin Pathol 60(7):756-61.
Ha,L.,T.Ichikawa,et al.(2007)."ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence." Proc Natl Acad Sci U S A 104(26):10968-73.
Hall,P.,A.Ploner,et al.(2006)."Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis:a cohort study." BMC Med 4:16.
Hutter,G.,M.Scheubner,et al.(2006)."Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors[p16(INK4a),p15(INK4b),p14(ARF)]in mantle cell lymphoma." Genes Chromosomes Cancer 45(2):203-10.
Jones,P.A.and S.M.Taylor(1980)."Cellular differentiation,cytidine analogs and DNA methylation." Cell 20(1):85-93.
Kerlikowske,K.,D.Grady,et al.(1996)."Likelihood ratios for modern screening mammography.Risk of breast cancer based on age and mammographic interpretation." Jama 276(1):39-43.
Kleer,C.G.,Q.Cao,et al.(2003)."EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells." Proc Natl Acad Sci U S A 100(20):11606-11.
Kriege,M.,C.T.Brekelmans,et al.(2004)."Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition." N Engl J Med 351(5):427-37.
Li,Y.,H.Nagai,et al.(2002)."Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype." Blood 100(7):2572-7.
Marks,P.A.,V.M.Richon,et al.(2004)."Histone deacetylase inhibitors." Adv Cancer Res 91:137-68.
Matsukawa,Y.,S.Semba,et al.(2006)."Expression of the enhancer of zeste homolog 2is correlated with poor prognosis in human gastric cancer." Cancer Sci 97(6):484-91.
McGarvey,K.M.,J.A.Fahrner,et al.(2006)."Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state." Cancer Res 66(7):3541-9.
McGarvey,K.M.,E.Greene,et al.(2007)."DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2." Cancer Res 67(11):5097-102.
Medh,R.D.,A.Wang,et al.(2001)."Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells." Oncogene 20(34):4629-39.
Mikkelsen,T.S.,M.Ku,et al.(2007)."Genome-wide maps of chromatin state in pluripotent and lineage-committed cells." Nature 448(7153):553-60.
Miller,A.B.,T.To,et al.(2002)."The Canadian National Breast Screening Study-1:breast cancer mortality after 11 to 16 years of follow-up.A randomized screening trial of mammography in women age 40 to 49 years." Ann Intern Med 137(5 Part 1):305-12.
Miller,L.D.,J.Smeds,et al.(2005)."An expression signature for p53 status in human breast cancer predicts mutation status,transcriptional effects,and patient survival." Proc Natl Acad Sci U S A 102(38):13550-5.
Nystrom,L.,I.Andersson,et al.(2002)."Long-term effects of mammography screening:updated overview of the Swedish randomised trials." Lancet 359(9310):909-19.
Ohm,J.E.,K.M.McGarvey,et al.(2007)."A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing." Nat Genet 39(2):237-42.
Ooi,S.K.,C.Qiu,et al.(2007)."DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA." Nature 448(7154):714-7.
Pan,G.(2007)."Whole-Genome Analysis of Histone H3 Lysine 4 and Lysine 27Methylation in Human Embryonic Stem Cells." Cell Stem Cell 1:299-312.
Pateras,I.S.,K.Apostolopoulou,et al.(2006)."Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer." Int J Cancer 119(11):2546-56.
Pei,X.H.,F.Bai,et al.(2007)."p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers." Cancer Res 67(7):3162-70.
Rosenberg,R.D.,W.C.Hunt,et al.(1998)."Effects of age,breast density,ethnicity,and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis:review of 183,134 screening mammograms in Albuquerque,New Mexico." Radiology 209(2):511-8.
Sanchez-Aguilera,A.,J.Delgado,et al.(2004)."Silencing of the p 18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas."Blood 103(6):2351-7.
Schlesinger,Y.,R.Straussman,et al.(2007)."Polycomb-mediated methylation on Lys27of histone H3 pre-marks genes for de novo methylation in cancer." Nat Genet 39(2):232-6.
Shames,D.S.,L.Girard,et al.(2006)."A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies."PLoS Med 3(12):e486.
Soejima,H.,T.Nakagawachi,et al.(2004)."Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer." Oncogene 23(25):4380-8.
Tan,J.,X.Yang,et al.(2007)."Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells." Genes Dev 21(9):1050-63.
Varambally,S.,S.M.Dhanasekaran,et al.(2002)."The polycomb group protein EZH2 is involved in progression of prostate cancer." Nature 419(6907):624-9.
Vire,E.,C.Brenner,et al.(2006)."The Polycomb group protein EZH2 directly controls DNA methylation." Nature 439(7078):871-4.
Weber,M.,I.Hellmann,et al.(2007)."Distribution,silencing potential and evolutionary impact of promoter DNA methylation in the human genome." Nat Genet 39(4):457-66.
Widschwendter,M.,H.Fiegl,et al.(2007)."Epigenetic stem cell signature in cancer."Nat Genet 39(2):157-8.
Wozniak,R.J.,W.T.Klimecki,et al.(2007)."5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation." Oncogene 26(1):77-90.
Yu,J.,D.R.Rhodes,et al.(2007)."A polycomb repression signature in metastatic prostate cancer predicts cancer outcome." Cancer Res 67(22):10657-63.
Zahl,P.H.,B.H.Strand,et al.(2004)."Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening:prospective cohort study."Bmj 328(7445):921-4.
Zhao,X.D.(2007)."Whole-Genome Mapping of Histone H3Lys4and27 Trimethylations Reveals Distinct Genomic Compartments in Human Embryonic Stem Cells." Cell Stem Cell 1:286-298.
Agger,K.,P.A.Cloos,et al.(2007)."UTX and JMJD3 are histone H3K27demethylases involved in HOX gene regulation and development." Nature 449(7163):731-4.
Ahn,M.Y.,J.H.Jung,et al.(2008)."A natural histone deacetylase inhibitor,Psammaplin A,induces cell cycle arrest and apoptosis in human endometrial cancer cells." Gynecol Oncol 108(1):27-33.
Al-Hajj,M.,M.S.Wicha,et al.(2003)."Prospective identification of tumorigenic breast cancer cells." Proc Natl Acad Sci U S A 100(7):3983-8.
Allfrey,V.G.,R.Faulkner,et al.(1964)."Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis." Proc Natl Acad Sci U S A 51:786-94.
Arce,C.,B.Segura-Pacheco,et al.(2006)."Hydralazine target:from blood vessels to the epigenome." J Transl Med 4:10.
Bachman,K.E.,B.H.Park,et al.(2003)."Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene." Cancer Cell 3(1):89-95.
Ballestar,E.and M.Esteller(2005)."Methyl-CpG-binding proteins in cancer:blaming the DNA methylation messenger." Biochem Cell Biol 83(3):374-84.
Bannister,A.J.and T.Kouzarides(1996)."The CBP co-activator is a histone acetyltransferase." Nature 384(6610):641-3.
Barski,A.,S.Cuddapah,et al.(2007)."High-resolution profiling of histone methylations in the human genome." Cell 129(4):823-37.
Baylin,S.B.and J.E.Ohm(2006)."Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?" Nat Rev Cancer 6(2):107-16.
Beach,R.,A.O.Chan,et al.(2005)."BRAF mutations in aberrant crypt foci and hyperplastic polyposis." Am J Pathol 166(4):1069-75.
Belinsky,S.A.,K.J.Nikula,et al.(1998)."Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis." Proc Natl Acad Sci U S A 95(20):11891-6.
Benbrahim-Tallaa,L.,R.A.Waterland,et al.(2007)."Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase." Environ Health Perspect 115(10):1454-9.
Berletch,J.B.,C.Liu,et al.(2008)."Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG." J Cell Biochem 103(2):509-19.
Bernstein,B.E.,T.S.Mikkelsen,et al.(2006)."A bivalent chromatin structure marks key developmental genes in embryonic stem cells." Cell 125(2):315-26.
Bernstein,E.and C.D.Allis(2005)."RNA meets chromatin." Genes Dev 19(14):1635-55.
Bird,A.(2002)."DNA methylation patterns and epigenetic memory." Genes Dev 16(1):6-21.
Bird,A.P.(1986)."CpG-rich islands and the function of DNA methylation."Nature 321(6067):209-13.
Bolden,J.E.,M.J.Peart,et al.(2006)."Anticancer activities of histone deacetylase inhibitors." Nat Rev Drug Discov 5(9):769-84.
Bourc'his,D.and T.H.Bestor(2004)."Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L."Nature 431(7004):96-9.
Bourc'his,D.,G.L.Xu,et al.(2001)."Dnmt3L and the establishment of maternal genomic imprints." Science 294(5551):2536-9.
Boyer,L.A.,K.Plath,et al.(2006)."Polycomb complexes repress developmental regulators in murine embryonic stem cells." Nature 441(7091):349-53.
Brena,R.M.and J.F.Costello(2007)."Genome-epigenome interactions in cancer." Hum Mol Genet 16 Spec No 1:R96-105.
Brownell,J.E.and C.D.Allis(1995)."An activity gel assay detects a single,catalytically active histone acetyltransferase subunit in Tetrahymena macronuclei." Proc Natl Acad SciUSA92(14):6364-8.
Brueckner,B.,R.G.Boy,et al.(2005)."Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases."Cancer Res 65(14):6305-11.
Brueckner,B.,C.Stresemann,et al.(2007)."The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function." Cancer Res 67(4):1419-23.
Cairns,P.(2007)."Gene methylation and early detection of genitourinary cancer:the road ahead." Nat Rev Cancer 7(7):531-43.
Candido,E.P.,R.Reeves,et al.(1978)."Sodium butyrate inhibits histone deacetylation in cultured cells." Cell 14(1):105-13.
Cao,R.,L.Wang,et al.(2002)."Role of histone H3 lysine 27 methylation in Polycomb-group silencing." Science 298(5595):1039-43.
Cao,R.and Y.Zhang(2004)."The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3." Curr Opin Genet Dev 14(2):155-64.
Cheng,J.C.,C.B.Matsen,et al.(2003)."Inhibition of DNA methylation and reactivation of silenced genes by zebularine."J Natl Cancer Inst 95(5):399-409.
Constantinides,P.G.,P.A.Jones,et al.(1977)."Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment." Nature 267(5609):364-6.
Cuthbert,G.L.,S.Daujat,et al.(2004)."Histone deimination antagonizes arginine methylation." Cell 118(5):545-53.
Dalerba,P.,R.W.Cho,et al.(2007)."Cancer stem cells:models and concepts."Annu Rev Med 58:267-84.
Dalerba,P.,C.Maccalli,et al.(2003)."Immunology and immunotherapy of colorectal cancer." Crit Rev Oncol Hematol 46(1):33-57.
Dancey,J.E.and H.X.Chen(2006)."Strategies for optimizing combinations of molecularly targeted anticancer agents." Nat Rev Drug Discov 5(8):649-59.
de la Cruz-Hemandez,E.,E.Perez-Cardenas,et al.(2007)."The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer,an in vitro and clinical study." Virol J 4:18.
De Santa,F.,M.G.Totaro,et al.(2007)."The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing." Cell 130(6):1083-94.
Dellino,G.I.,Y.B.Schwartz,et al.(2004)."Polycomb silencing blocks transcription initiation." Mol Cell 13(6):887-93.
Duan,H.,C.A.Heckman,et al.(2005)."Histone deacetylase inhibitors downregulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas." Mol Cell Biol 25(5):1608-19.
Egger,G.,G.Liang,et al.(2004)."Epigenetics in human disease and prospects for epigenetic therapy." Nature 429(6990):457-63.
Espada,J.and M.Esteller(2007)."Epigenetic control of nuclear architecture." Cell Mol Life Sci 64(4):449-57.
Esteller,M.(2007)."Cancer epigenomics:DNA methylomes and histonemodification maps." Nat Rev Genet 8(4):286-98.
Fabbri,M.,R.Garzon,et al.(2007)."MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B." Proc Natl Acad Sci U S A 104(40):15805-10.
Fahrner,J.A.,S.Eguchi,et al.(2002),"Dependence of histone modifications and gene expression on DNA hypermethylation in cancer." Cancer Res 62(24):7213-8.
Fearon,E.R.and B.Vogelstein(1990)."A genetic model for colorectal tumorigenesis." Cell 61(5):759-67.
Feinberg,A.P.(2007)."Phenotypic plasticity and the epigenetics of human disease." Nature 447(7143):433-40.
Feinberg,A.P.and B.Tycko(2004)."The history of cancer epigenetics." Nat Rev Cancer 4(2):143-53.
Feinberg,A.P.and B.Vogelstein(1983)."Hypomethylation distinguishes genes of some human cancers from their normal counterparts." Nature 301(5895):89-92.
Fraga,M.F.,E.Ballestar,et al.(2005)."Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer." Nat Genet 37(4):391-400.
Francis,N.J.and R.E.Kingston(2001)."Mechanisms of transcriptional memory."Nat Rev Mol Cell Biol 2(6):409-21.
Gal-Yam,E.N.,Y.Saito,et al.(2007)."Cancer Epigenetics:Modifications,Screening,and Therapy." Annu Rev Med.
Gershey,E.L.,G.Vidali,et al.(1968)."Chemical studies of historic acetylation.The occurrence of epsilon-N-acetyllysine in the f2al histone." J Biol Chem 243(19):5018-22.
Gifford,G.,J.Paul,et al.(2004)."The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients."Clin Cancer Res 10(13):4420-6.
Glaser,K.B.(2007)."HDAC inhibitors:Clinical update and mechanism-based potential." Biochem Pharmacol 74(5):659-71.
Glozak,M.A.and E.Seto(2007)."Histone deacetylases and cancer." Oncogene 26(37):5420-32.
Gonzalez-Zulueta,M.,C.M.Bender,et al.(1995)."Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing." Cancer Res 55(20):4531-5.
Gowher,H.and A.Jeltsch(2004)."Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy." Cancer Biol Ther 3(11):1062-8.
Greger,V.,E.Passarge,et al.(1989)."Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma." Hum Genet 83(2):155-8.
Gregoretti,I.V.,Y.M.Lee,et al.(2004)."Molecular evolution of the histone deacetylase family:functional implications of phylogenetic analysis." J Mol Biol 338(1):17-31.
Guan,Y.,B.Gerhard,et al.(2003)."Detection,isolation,and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)." Blood 101(8):3142-9.
Guzman,M.L.,C.F.Swiderski,et al.(2002)."Preferential induction of apoptosis for primary human leukemic stem cells." Proc Natl Acad Sci U S A 99(25):16220-5.
Hanahan,D.and R.A.Weinberg(2000)."The hallmarks of cancer." Cell 100(1):57-70.
Hassa,P.O.,S.S.Haenni,et al.(2006)."Nuclear ADP-ribosylation reactions in mammalian cells:where are we today and where are we going?" Microbiol Mol Biol Rev 70(3):789-829.
Hazzalin,C.A.and L.C.Mahadevan(2005)."Dynamic acetylation of all lysine 4-methylated histone H3 in the mouse nucleus:analysis at c-fos and c-jun." PLoS Biol 3(12):e393.
Hinshelwood,R.A.,L.I.Huschtscha,et al.(2007)."Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis." Cancer Res 67(24):11517-27.
Hitchins,M.P.,V.A.Lin,et al.(2007)."Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer." Cancer Res 67(19):9107-16.
Holleran,J.L.,R.A.Parise,et al.(2005)."Plasma pharmacokinetics,oral bioavailability,and interspecies scaling of the DNA methyltransferase inhibitor,zebularine." Clin Cancer Res 11(10):3862-8.
Issa,J.P.(2004)."CpG island methylator phenotype in cancer." Nat Rev Cancer 4(12):988-93.
Issa,J.P.and H.Kantarjian(2005)."Azacitidine." Nat Rev Drug Discov Suppl:S6-7.
Issa,J.P.,H.M.Kantarjian,et al.(2005)."Azacitidine." Nat Rev Drug Discov 4(4):275-6.
Jeltsch,A.(2006)."Molecular enzymology of mammalian DNA methyltransferases." Curr Top Microbiol Immunol 301:203-25.
Jia,D.,R.Z.Jurkowska,et al.(2007)."Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation." Nature 449(7159):248-51.
Jones,P.A.and S.B.Baylin(2002)."The fundamental role of epigenetic events in cancer." Nat Rev Genet 3(6):415-28.
Jones,P.A.and S.B.Baylin(2007)."The epigenomics of cancer." Cell 128(4):683-92.
Jones,P.A.and P.W.Laird(1999)."Cancer epigenetics comes of age." Nat Genet 21(2):163-7.
Joseph,J.,G.Mudduluru,et al.(2004)."Expression profiling of sodium butyrate (NaB)-treated cells:identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB." Oncogene 23(37):6304-15.
Kane,M.F.,M.Loda,et al.(1997)."Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines." Cancer Res 57(5):808-11.
Kaneda,A.and A.P.Feinberg(2005)."Loss of imprinting of IGF2:a common epigenetic modifier of intestinal tumor risk." Cancer Res 65(24):11236-40.
Kaneda,M.,M.Okano,et al.(2004)."Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting." Nature 429(6994):900-3.
Kantarjian,H.,J.P.Issa,et al.(2006)."Decitabine improves patient outcomes in myelodysplastic syndromes:results of a phase Ⅲ randomized study." Cancer 106(8):1794-803.
Kantarjian,H.,Y.Oki,et al.(2007)."Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia." Blood 109(1):52-7.
Kavi,H.H.,H.R.Fernandez,et al.(2005)."RNA silencing in Drosophila." FEBS Lett 579(26):5940-9.
Kawasaki,H.and K.Taira(2004)."Induction of DNA methylation and gene silencing by short interfering RNAs in human cells." Nature 431(7005):211-7.
Kennison,J.A.(1995)."The Polycomb and trithorax group proteins of Drosophila:trans-regulators of homeotic gene function." Annu Rev Genet 29:289-303.
Kennison,J.A.(2004)."Introduction to Trx-G and Pc-G genes." Methods Enzymol 377:61-70.
Kleff,S.,E.D.Andrulis,et al.(1995)."Identification of a gene encoding a yeast historic H4 acetyltransferase." J Biol Chem 270(42):24674-7.
Klose,R.J.,E.M.Kallin,et al.(2006)."JmjC-domain-containing proteins and histone demethylation." Nat Rev Genet 7(9):715-27.
Klymenko,T.,B.Papp,et al.(2006)."A Polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysine-binding activities." Genes Dev 20(9):1110-22.
Kondo,Y.,L.Shen,et al.(2004)."Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation." Proc Natl Acad Sci U S A 101(19):7398-403.
Kouzarides,T.(2007)."Chromatin modifications and their function." Cell 128(4):693-705.
Kouzarides,T.(2007)."SnapShot:Histone-Modifying Enzymes." Cell 131(4):822.
Lan,F.,P.E.Bayliss,et al.(2007)."A histone H3 lysine 27 demethylase regulates animal posterior development." Nature 449(7163):689-94.
Lapidot,T.,C.Sirard,et al.(1994)."A cell initiating human acute myeloid leukaemia after transplantation into SCID mice." Nature 367(6464):645-8.
Lee,B.H.,S.Yeguasubramanian,et al.(2005)."Procainamide is a specific inhibitor of DNA methyltransferase 1." J Biol Chem 280(49):40749-56.
Lee,K.K.and J.L.Workman(2007)."Histone acetyltransferase complexes:one size doesn't fit all." Nat Rev Mol Cell Biol 8(4):284-95.
Lee,M.G.,R.Villa,et al.(2007)."Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination." Science 318(5849):447-50.
Lee,T.I.,R.G.Jenner,et al.(2006)."Control of developmental regulators by Polycomb in human embryonic stem cells." Cell 125(2):301-13.
Leonhardt,H.,A.W.Page,et al.(1992)."A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei." Cell 71(5):865-73.
Liang,G.,J.C.Lin,et al.(2004)."Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome." Proc Natl Acad Sci U S A 101(19):7357-62.
Liu,Y.,E.J.Oakeley,et al.(1998)."Multiple domains are involved in the targeting of the mouse DNA methyltransferase to the DNA replication foci." Nucleic Acids Res 26(4):1038-45.
Lujambio,A.,S.Ropero,et al.(2007)."Genetic unmasking of an epigenetically silenced microRNA in human cancer cells." Cancer Res 67(4):1424-9.
Mancini,D.N.,D.I.Rodenhiser,et al.(1998)."CpG methylation within the 5'regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site." Oncogene 16(9):1161-9.
Mattick,J.S.and I.V.Makunin(2006)."Non-coding RNA." Hum Mol Genet 15Spec No 1:R17-29.
McGarvey,K.M.,J.A.Fahrner,et al.(2006)."Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state."Cancer Res 66(7):3541-9.
Metivier,R.,G.Penot,et al.(2003)."Estrogen receptor-alpha directs ordered,cyclical,and combinatorial recruitment of cofactors on a natural target promoter." Cell 115(6):751-63.
Miao,F.and R.Natarajan(2005)."Mapping global histone methylation patterns in the coding regions of human genes." Mol Cell Biol 25(11):4650-61.
Michaelis,M.,U.R.Michaelis,et al.(2004)."Valproic acid inhibits angiogenesis in vitro and in vivo." Mol Pharmacol 65(3):520-7.
Mikkelsen,T.S.,M.Ku,et al.(2007)."Genome-wide maps of chromatin state in pluripotent and lineage-committed cells." Nature 448(7153):553-60.
Mimeault,M.,R.Hauke,et al.(2007)."Recent advances in cancer stem/progenitor cell research:therapeutic implications for overcoming resistance to the most aggressive cancers." J Cell Mol Med 11(5):981-1011.
Moiseeva,E.P.,G.M.Almeida,et al.(2007)."Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression,reduced growth,and apoptosis of cancer cells." Mol Cancer Ther 6(11):3071-9.
Morris,K.V.,S.W.Chan,et al.(2004)."Small interfering RNA-induced transcriptional gene silencing in human cells." Science 305(5688):1289-92.
Morrison,S.J.and I.L.Weissman(1994)."The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype." Immunity 1(8):661-73.
Nathan,D.,K.Ingvarsdottir,et al.(2006)."Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications." Genes Dev 20(8):966-76.
Nebbioso,A.,N.Clarke,et al.(2005)."Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells." Nat Med 11(1):77-84.
Nelson,C.J.,H.Santos-Rosa,et al.(2006)."Proline isomerization of histone H3regulates lysine methylation and gene expression." Cell 126(5):905-16.
Nguyen,C.T.,D.J.Weisenberger,et al.(2002)."Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine."Cancer Res 62(22):6456-61.
Nightingale,K.P.,L.P.O'Neill,et al.(2006)."Histone modifications:signalling receptors and potential elements of a heritable epigenetic code." Curr Opin Genet Dev 16(2):125-36.
Nowak,S.J.and V.G.Corces(2004)."Phosphorylation of histone H3:a balancing act between chromosome condensation and transcriptional activation." Trends Genet 20(4):214-20.
Nowell,P.C.(1989)."The clonal nature of neoplasia." Cancer Cells 1(1):29-30.
Nuovo,G.J.,T.W.Plaia,et al.(1999)."In situ detection of the hypermethylationinduced inactivation of the p16 gene as an early event in oncogenesis." Proc Natl Acad Sci U S A 96(22):12754-9.
Ohm,J.E.,K.M.McGarvey,et al.(2007)."A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing."Nat Genet 39(2):237-42.
Okano,M.,D.W.Bell,et al.(1999)."DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development." Cell 99(3):247-57.
Ooi,S.K.,C.Qiu,et al.(2007)."DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA." Nature 448(7154):714-7.
Ozdag,H.,A.E.Teschendorff,et al.(2006)."Differential expression of selected histone modifier genes in human solid cancers." BMC Genomics 7:90.
Peart,M.J.,G.K.Smyth,et al.(2005)."Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors." Proc Natl Acad Sci U S A 102(10):3697-702.
Phillips,D.M.(1963)."The presence of acetyl groups of histones." Biochem J 87:258-63.
Pina,I.C.,J.T.Gautschi,et al.(2003)."Psammaplins from the sponge Pseudoceratina purpurea:inhibition of both histone deacetylase and DNA methyltransferase." J Org Chem 68(10):3866-73.
Pirrotta,V.(1999)."Polycomb silencing and the maintenance of stable chromatin states." Results Probl Cell Differ 25:205-28.
Qiu,L.,A.Burgess,et al.(2000)."Histone deacetylase inhibitors trigger a G2checkpoint in normal cells that is defective in tumor cells." Mol Biol Cell 11(6):2069-83.
Rea,S.,F.Eisenhaber,et al.(2000)."Regulation of chromatin structure by sitespecific histone H3 methyltransferases." Nature 406(6796):593-9.
Reik,W.,W.Dean,et al.(2001)."Epigenetic reprogramming in mammalian development." Science 293(5532):1089-93.
Ricci-Vitiani,L.,D.G.Lombardi,et al.(2007)."Identification and expansion of human colon-cancer-initiating cells." Nature 445(7123):111-5.
Richon,V.M.,T.W.Sandhoff,et al.(2000)."Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation." Proc Natl Acad Sci U S A 97(18):10014-9.
Rocchi,P.,R.Tonelli,et al.(2005)."p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors(valproic acid,tributyrin and sodium butyrate) in neuroblastoma cells." Oncol Rep 13(6):1139-44.
Roh,T.Y.,S.Cuddapah,et al.(2006)."The genomic landscape of histone modifications in human T cells." Proc Natl Acad Sci U S A 103(43):15782-7.
Roh,T.Y.,W.C.Ngau,et al.(2004)."High-resolution genome-wide mapping of histone modifications." Nat Biotechnol 22(8):1013-6.
Ropero,S.,M.F.Fraga,et al.(2006)."A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition." Nat Genet 38(5):566-9.
Sakajiri,S.,T.Kumagai,et al.(2005)."Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines." Exp Hematol 33(1):53-61.
Santos-Rosa,H.,R.Schneider,et al.(2002)."Active genes are tri-methylated at K4of histone H3." Nature 419(6905):407-11.
Saurin,A.J.,Z.Shao,et al.(2001)."A Drosophila Polycomb group complex includes Zeste and dTAFII proteins." Nature 412(6847):655-60.
Schlesinger,Y.,R.Straussman,et al.(2007)."Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer." Nat Genet 39(2):232-6.
Seligson,D.B.,S.Horvath,et al.(2005)."Global histone modification patterns predict risk of prostate cancer recurrence." Nature 435(7046):1262-6.
Shi,Y.and J.R.Whetstine(2007)."Dynamic regulation of historic lysine methylation by demethylases." Mol Cell 25(1):1-14.
Shilatifard,A.(2006)."Chromatin modifications by methylation and ubiquitination:implications in the regulation of gene expression." Armu Rev Biochem 75:243-69.
Smallwood,A.,P.O.Esteve,et al.(2007)."Functional cooperation between HP1and DNMT1 mediates gene silencing." Genes Dev 21(10):1169-78.
Soriano,A.O.,H.Yang,et al.(2007)."Safety and clinical activity of the combination of 5-azacytidine,valproic acid,and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome." Blood 110(7):2302-8.
Sorm,F.,A.Piskala,et al.(1964)."5-Azacytidine,a new,highly effective cancerostatic." Experientia 20(4):202-3.
Sterner,D.E.and S.L.Berger(2000)."Acetylation of histones and transcriptionrelated factors." Microbiol Mol Biol Rev 64(2):435-59.
Suzuki,H.,E.Gabrielson,et al.(2002)."A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer." Nat Genet 31(2):141-9.
Ting,A.H.,K.M.McGarvey,et al.(2006)."The cancer epigenome—components and functional correlates." Genes Dev 20(23):3215-31.
Toyoda,A.,H.Noguchi,et al.(2002)."Comparative genomic sequence analysis of the human chromosome 21 Down syndrome critical region." Genome Res 12(9):1323-32.
Turner,B.M.(2007)."Defining an epigenetic code." Nat Cell Biol 9(1):2-6.
van Leenders,G.J.,D.Dukers,et al.(2007)."Polycomb-group oncogenes EZH2,BMI1,and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features." Eur Urol 52(2):455-63.
Varambally,S.,S.M.Dhanasekaran,et al.(2002)."The polycomb group protein EZH2 is involved in progression of prostate cancer." Nature 419(6907):624-9.
Venturelli,S.,S.Armeanu,et al.(2007)."Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma." Cancer 109(10):2132-41.
Vire,E.,C.Brenner,et al.(2006)."The Polycomb group protein EZH2 directly controls DNA methylation." Nature 439(7078):871-4.
Volkel,P.and P.O.Angrand(2007)."The control of histone lysine methylation in epigenetic regulation." Biochimie 89(1):1-20.
Wang,L.,J.L.Brown,et al.(2004)."Hierarchical recruitment of polycomb group silencing complexes." Mol Cell 14(5):637-46.
Weisenberger,D.J.,K.D.Siegmund,et al.(2006)."CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer." Nat Genet 38(7):787-93.
Wilson,A.S.,B.E.Power,et al.(2007)."DNA hypomethylation and human diseases." Biochim Biophys Acta 1775(1):138-62.
Wu,H.,Y.Chen,et al.(2005)."Hypomethylation-linked activation of PAX2mediates tamoxifen-stimulated endometrial carcinogenesis." Nature 438(7070):981-7.
Yamada,Y.,L.Jackson-Grusby,et al.(2005)."Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis." Proc Natl Acad Sci U S A 102(38):13580-5.
Yang,X.J.and E.Seto(2007)."HATs and HDACs:from structure,function and regulation to novel strategies for therapy and prevention." Oncogene 26(37):5310-8.
Yoo,C.B.and P.A.Jones(2006)."Epigenetic therapy of cancer:past,present and future." Nat Rev Drug Discov 5(1):37-50.
Yu,J.,Q.Cao,et al.(2007)."Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer." Cancer Cell 12(5):419-31.
Yu,J.,D.R.Rhodes,et al.(2007)."A polycomb repression signature in metastatic prostate cancer predicts cancer outcome." Cancer Res 67(22):10657-63.
Zambrano,P.,B.Segura-Pacheco,et al.(2005)."A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes." BMC Cancer 5(1):44.
Zhang,Y.and D.Reinberg(2001)."Transcription regulation by histone methylation:interplay between different covalent modifications of the core histone tails." Genes Dev 15(18):2343-60.
Zhao,Y.,J.Tan,et al.(2005)."Inhibitors of histone deacetylases target the RbE2F1pathway for apoptosis induction through activation of proapoptotic protein Bim."Proc Natl Acad Sci U S A 102(44):16090-5.
Bieda,M.,X.Xu,et al.(2006)."Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome." Genome Res 16(5):595-605.
Boutillier,A.L.,E.Trinh,et al.(2003)."Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis." J Neurochem 84(4):814-28.
Bracken,A.P.,D.Pasini,et al.(2003)."EZH2 is downstream of the pRB-E2F pathway,essential for proliferation and amplified in cancer." Embo J 22(20):5323-35.
Brooks,W.H.,D.E.McCloskey,et al.(2007)."In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase." J Chem Inf Model 47(5):1897-905.
Cam,H.and B.D.Dynlacht(2003)."Emerging roles for E2F:beyond the G1/S transition and DNA replication." Cancer Cell 3(4):311-6.
Chiang,P.K.,P.D.Burbelo,et al.(1992)."Activation of collagen Ⅳ gene expression in F9 teratocarcinoma cells by 3-deazaadenosine analogs.Indirect inhibitors of methylation." J Biol Chem 267(7):4988-91.
Chiang,P.K.and G.L.Cantoni(1979)."Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo." Biochem Pharmacol 28(12):1897-902.
Chuikov,S.,J.K.Kurash,et al.(2004)."Regulation of p53 activity through lysine methylation." Nature 432(7015):353-60.
Dyson,N.(1998)."The regulation of E2F by pRB-family proteins." Genes Dev 12(15):2245-62.
Field,S.J.,F.Y.Tsai,et al.(1996)."E2F-1 functions in mice to promote apoptosis and suppress proliferation." Cell 85(4):549-61.
Fortin,A.,J.G.MacLaurin,et al.(2004)."The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1." J Biol Chem 279(27):28706-14.
Furukawa,Y.,N.Nishimura,et al.(2002)."Apaf-1 is a mediator of E2F-1-induced apoptosis." J Biol Chem 277(42):39760-8.
Gasparetto,M.,T.Gentry,et al.(2004)."Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow eytometric high-content screening." J Immunol Methods 292(1-2):59-71.
Glazer,R.I.,M.C.Knode,et al.(1986)."3-Deazaneplanocin A:a new inhibitor of Sadenosylhomocysteine synthesis and its effects in human colon carcinoma cells."Biochem Pharmacol 35(24):4523-7.
Hall,M.and G.Peters(1996)."Genetic alterations of cyclins,cyclin-dependent kinases,and Cdk inhibitors in human cancer." Adv Cancer Res 68:67-108.
Hao,H.,Y.Dong,et al.(2007)."E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation." BMC Cancer 7:24.
Hershko,T.and D.Ginsberg(2004)."Up-regulation of Bcl-2 homology 3(BH3)-only proteins by E2F1 mediates apoptosis." J Biol Chem 279(10):8627-34.
Holbeck,S.L.(2004)."Update on NCI in vitro drug screen utilities." Eur J Cancer 40(6):785-93.
Huang,C.L.,D.Liu,et al.(2007)."E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer." Clin Cancer Res 13(23):6938-46.
Irwin,M.,M.C.Marin,et al.(2000)."Role for the p53 homologue p73 in E2F-1-induced apoptosis." Nature 407(6804):645-8.
Johnson,D.G.and J.Degregori(2006)."Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context." Curr Mol Med 6(7):731-8.
Kraker,A.J.,C.A.Mizzen,et al.(2003)."Modulation ofhistone acetylation by[4-(acetylamino)-N-(2-amino-phenyl)benzamide]in HCT-8 colon carcinoma." Mol Cancer Ther 2(4):401-8.
Lowe,S.W.,E.Cepero,et al.(2004)."Intrinsic tumour suppression." Nature 432(7015):307-15.
Lu,Z.,R.Z.Luo,et al.(2006)."E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer." Oncogene 25(2):230-9.
Moroni,M.C.,E.S.Hickman,et al.(2001)."Apaf-1 is a transcriptional target for E2F and p53." Nat Cell Biol 3(6):552-8.
Mundle,S.D.and G.Saberwal(2003)."Evolving intricacies and implications of E2F1regulation." Faseb J 17(6):569-74.
Nahle,Z.,J.Polakoff,et al.(2002)."Direct coupling of the cell cycle and cell death machinery by E2F." Nat Cell Biol 4(11):859-64.
Pediconi,N.,A.Ianari,et al.(2003)."Differential regulation of E2F1 apoptotic target genes in response to DNA damage." Nat Cell Biol 5(6):552-8.
Powers,J.T.,S.Hong,et al.(2004)."E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis." Mol Cancer Res 2(4):203-14.
Rayman,J.B.,Y.Takahashi,et al.(2002)."E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex." Genes Dev 16(8):933-47.
Real,P.J.,C.Sanz,et al.(2006)."Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells." FEBS Lett 580(25):5905-9.
Robertson,K.D.,S.Ait-Si-Ali,et al.(2000)."DNMT1 forms a complex with Rb,E2F1and HDAC1 and represses transcription from E2F-responsive promoters." Nat Genet 25(3):338-42.
Rogoff,H.A.,M.T.Picketing,et al.(2002)."E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis." Mol Cell Biol 22(15):5308-18.
Rogoff,H.A.,M.T.Picketing,et al.(2004)."Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbsl/Chk2." Mol Cell Biol 24(7):2968-77.
Sherr,C.J.(1996)."Cancer cell cycles." Science 274(5293):1672-7.
Stiewe,T.and B.M.Putzer(2000)."Role of the p53-homologue p73 in E2F1-induced apoptosis." Nat Genet 26(4):464-9.
Tan,J.,L.Zhuang,et al.(2006)."Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity." J Biol Chem 281(15):10508-15.
Trimarchi,J.M.and J.A.Lees(2002)."Sibling rivalry in the E2F family." Nat Rev Mol Cell Biol 3(1):11-20.
Tyagi,S.,A.L.Chabes,et al.(2007)."E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4methyltransferases." Mol Cell 27(1):107-19.
Xiao,Q.,L.Li,et al.(2007)."Transcription factor E2F-1 is upregulated in human gastric cancer tissues and its overexpression suppresses gastric tumor cell proliferation."Cell Oncol 29(4):335-49.
Xie,W.,P.Jiang,et al.(2006)."Novel link between E2F1 and Smac/DIABLO:proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1." Nucleic Acids Res 34(7):2046-55.
Yamasaki,L.,T.Jacks,et al.(1996)."Tumor induction and tissue atrophy in mice lacking E2F-1." Cell 85(4):537-48.
Zhao,Y.,J.Tan,et al.(2005)."Inhibitors ofhistone deacetylases target the Rb-E2F1pathway for apoptosis induction through activation ofproapoptotic protein Bim."Proc Natl Acad Sci U S A 102(44):16090-5.
Zhu,J.W.,D.DeRyckere,et al.(1999)."A role for E2F1 in the induction of ARF,p53,and apoptosis during thymic negative selection." Cell Growth Differ 10(12):829-38.
Zhu,W.,P.H.Giangrande,et al.(2004)."E2Fs link the control of G1/S and G2/M transcription." Embo J 23(23):4615-26.
Allred,D.C.,S.K.Mohsin,et al.(2001)."Histological and biological evolution of human premalignant breast disease." Endocr Relat Cancer 8(1):47-61.
Beisel,C.,A.Imhof,et al.(2002)."Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1." Nature 419(6909):857-62.
Bemstein,B.E.,T.S.Mikkelsen,et al.(2006)."A bivalent chromatin structure marks key developmental genes in embryonic stem cells." Cell 125(2):315-26.
Boyer,L.A.,K.Plath,et al.(2006)."Polycomb complexes repress developmental regulators in murine embryonic stem cells." Nature.
Bracken,A.P.,N.Dietrich,et al.(2006)."Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions." Genes Dev 20(9):1123-36.
Bracken,A.P.,D.Pasini,et al.(2003)."EZH2 is downstream of the pRB-E2F pathway,essential for proliferation and amplified in cancer." Embo J 22(20):5323-35.
Bray,M.,J.Driscoll,et al.(2000)."Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor."Antiviral Res 45(2):135-47.
Burstein,H.J.,K.Polyak,et al.(2004)."Ductal carcinoma in situ of the breast." N Engl J Med 350(14):1430-41.
Cao,R.,L.Wang,et al.(2002)."Role of histone H3 lysine 27 methylation in Polycomb-group silencing." Science 298(5595):1039-43.
Cao,R.and Y.Zhang(2004)."SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex." Mol Cell 15(1):57-67.
Cheema,B.,C.A.Gaul,et al.(2007)."Progressive resistance training in breast cancer:a systematic review of clinical trials." Breast Cancer Res Treat.
Cheng,J.C.,C.B.Yoo,et al.(2004)."Preferential response of cancer cells to zebularine." Cancer Cell 6(2):151-8.
De Clercq,E.,M.Cools,et al.(1989)."Broad-spectrum antiviral activities of neplanocin A,3-deazaneplanocin A,and their 5'-nor derivatives." Antimicrob Agents Chemother 33(8):1291-7.
Ehrich,M.,M.R.Nelson,et al.(2005)."Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry." Proc Natl Acad Sci U S A 102(44):15785-90.
Fucito,A.,C.Lucchetti,et al.(2007)."Genetic and epigenetic alterations in breast cancer:What are the perspectives for clinical practice?" Int J Biochem Cell Biol.
Fujii,Y.,M.Yada,et al.(2006)."Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation." Cancer Sci 97(8):729-36.
Gil,J.,D.Bernard,et al.(2005)."Role of polycomb group proteins in stem cell self-renewal and cancer." DNA Cell Biol 24(2):117-25.
Glazer,R.I.,K.D.Hartman,et al.(1986)."3-Deazaneplanocin:a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60." Biochem Biophys Res Commun 135(2):688-94.
Haupt,Y.,W.S.Alexander,et al.(1991)."Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice." Cell 65(5):753-63.
Holden,C.(2006)."Development.Gene-suppressing proteins reveal secrets of stem cells." Science 312(5772):349.
Huh,J.I.,A.Calvo,et al.(2005)."Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms." Oncogene 24(5):790-800.
Imai,K.and A.Takaoka(2006)."Comparing antibody and small-molecule therapies for cancer." Nat Rev Cancer 6(9):714-27.
Jones,P.A.and S.B.Baylin(2007)."The epigenomics of cancer." Cell 128(4):683-92.
Kalantry,S.,K.C.Mills,et al.(2006)."The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation." Nat Cell Biol 8(2):195-202.
Kamangar,F.,G.M.Dores,et al.(2006)."Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world." J Clin Oncol 24(14):2137-50.
Kamminga,L.M.,L.V.Bystrykh,et al.(2006)."The Polycomb group gene Ezh2prevents hematopoietic stem cell exhaustion." Blood 107(5):2170-9.
Kennison,J.A.(1995)."The Polycomb and trithorax group proteins of Drosophila:transregulators of homeotic gene function." Annu Rev Genet 29:289-303.
Kirmizis,A.,S.M.Bartley,et al.(2003)."Identification of the polycomb group protein SU(Z) 12 as a potential molecular target for human cancer therapy." Mol Cancer Ther 2(1):113-21.
Kirmizis,A.,S.M.Bartley,et al.(2004)."Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27." Genes Dev 18(13):1592-605.
Kleer,C.G.,Q.Cao,et al.(2003)."EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells." Proc Natl Acad Sci U S A 100(20):11606-11.
Kuzmichev,A.,R.Margueron,et al.(2005)."Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation."Proc Natl Acad Sci U S A 102(6):1859-64.
Lee,T.I.,R.G.Jenner,et al.(2006)."Control of developmental regulators by Polycomb in human embryonic stem cells." Cell 125(2):301-13.
Lehnertz,B.,Y.Ueda,et al.(2003)."Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin." Curr Biol 13(14):1192-200.
Levine,S.S.,I.F.King,et al.(2004)."Division of labor in polycomb group repression."Trends Biochem Sci 29(9):478-85.
Lin,D.I.,O.Barbash,et al.(2006)."Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystaUin) complex." Mol Cell 24(3):355-66.
Lund,A.H.and M.van Lohuizen(2004)."Polycomb complexes and silencing mechanisms." Curr Opin Cell Biol 16(3):239-46.
Milne,T.A.,S.D.Briggs,et al.(2002)."MLL targets SET domain methyltransferase activity to Hox gene promoters." Mol Cell 10(5):1107-17.
Minella,A.C.and B.E.Clurman(2005)."Mechanisms of tumor suppression by the SCF(Fbw7)." Cell Cycle 4(10):1356-9.
Montgomery,N.D.,D.Yee,et al.(2005)."The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation." Curr Biol 15(10):942-7.
Muller,J.,C.M.Hart,et al.(2002)."Histone methyltransferase activity of a Drosophila Polycomb group repressor complex." Cell 111(2):197-208.
Nakamura,T.,T.Mori,et al.(2002)."ALL-1 is a historic methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation." Mol Cell 10(5):1119-28.
Pan,G.(2007)."Whole-Genome Analysis of Histone H3 Lysine 4 and Lysine 27Methylation in Human Embryonic Stem Cells." Cell Stem Cell 1:299-312.
Pasini,D.,A.P.Bracken,et al.(2004)."Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity." Embo J 23(20):4061-71.
Perou,C.M.,T.Sorlie,et al.(2000)."Molecular portraits of human breast tumours."Nature 406(6797):747-52.
Peters,A.H.,D.O'Carroll,et al.(2001)."Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability." Cell 107(3):323-37.
Pirrotta,V.(2006)."Polycomb silencing mechanisms and genomic programming." Ernst Schering Res Found Workshop(57):97-113.
Polyak,K.(2007)."Breast cancer:origins and evolution." J Clin Invest 117(11):3155-63.
Rea,S.,F.Eisenhaber,et al.(2000)."Regulation of chromatin structure by site-specific histone H3 methyltransferases." Nature 406(6796):593-9.
Rennert,G.,S.Bisland-Naggan,et al.(2007)."Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations." N Engl J Med 357(2):115-23.
Rhodes,D.R.,M.G.Sanda,et al.(2003)."Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer." J Natl Cancer Inst 95(9):661-8.
Schlesinger,Y.,R.Straussman,et al.(2007)."Polycomb-mediated methylation on Lys27of histone H3 pre-marks genes for de novo methylation in cancer." Nat Genet 39(2):232-6.
Sellers,W.R.and M.Loda(2002)."The EZH2 polycomb transcriptional repressor—a marker or mover of metastatic prostate cancer?" Cancer Cell 2(5):349-50.
Sorlie,T.,C.M.Perou,et al.(2001)."Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications." Proc Natl Acad Sci U S A 98(19):10869-74.
Sparmann,A.and M.van Lohuizen(2006)."Polycomb silencers control cell fate,development and cancer." Nat Rev Cancer 6(11):846-56.
Stitt,T.N.,D.Drujan,et al.(2004)."The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors." Mol Cell 14(3):395-403.
Tseng,C.K.,V.E.Marquez,et al.(1989)."Synthesis of 3-deazaneplanocin A,a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities." J Med Chem 32(7):1442-6.
Varambally,S.,S.M.Dhanasekaran,et al.(2002)."The polycomb group protein EZH2 is involved in progression of prostate cancer." Nature 419(6907):624-9.
Vargo-Gogola,T.and J.M.Rosen(2007)."Modelling breast cancer:one size does not fit all." Nat Rev Cancer 7(9):659-72.
Velicescu,M.,D.J.Weisenberger,et al.(2002)."Cell division is required for de novo methylation of CpG islands in bladder cancer cells." Cancer Res 62(8):2378-84.
Vire,E.,C.Brenner,et al.(2006)."The Polycomb group protein EZH2 directly controls DNA methylation." Nature 439(7078):871-4.
Welcker,M.,A.Orian,et al.(2004)."The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation." Proc Natl Acad Sci U S A 101(24):9085-90.
Widakowich,C.,E.de Azambuja,et al.(2007)."Molecular targeted therapies in breast cancer:where are we now?" Int J Biochem Cell Biol 39(7-8):1375-87.
Azuara,V.,P.Perry,et al.(2006)."Chromatin signatures of pluripotent cell lines." Nat Cell Biol 8(5):532-8.
Bachmann,I.M.,O.J.Halvorsen,et al.(2006)."EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium,prostate,and breast." J Clin Oncol 24(2):268-73.
Bernstein,B.E.,T.S.Mikkelsen,et al.(2006)."A bivalent chromatin structure marks key developmental genes in embryonic stem cells." Cell 125(2):315-26.
Chim,C.S.,T.K.Fung,et al.(2003)."Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS." Leukemia 17(12):2533-5.
Egger,G.,A.M.Aparicio,et al.(2007)."Inhibition of histone deacetylation does not block resilencing of p 16 after 5-aza-2'-deoxycytidine treatment." Cancer Res 67(1):346-53.
Elmore,J.G.,M.B.Barton,et al.(1998)."Ten-year risk of false positive screening mammograms and clinical breast examinations." N Engl J Med 338(16):1089-96.
Fahraeus,R.and D.P.Lane(1999)."The p 16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts." Embo J 18(8):2106-18.
Franklin,D.S.,V.L.Godfrey,et al.(1998)."CDK inhibitors p18(INK4c) and p27(Kip1)mediate two separate pathways to collaboratively suppress pituitary tumorigenesis." Genes Dev 12(18):2899-911.
Gamboa-Dominguez,A.,S.Seidl,et al.(2007)."Prognostic significance of p21WAF1/CIP1,p27Kip1,p53 and E-cadherin expression in gastric cancer." J Clin Pathol 60(7):756-61.
Ha,L.,T.Ichikawa,et al.(2007)."ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence." Proc Natl Acad Sci U S A 104(26):10968-73.
Hall,P.,A.Ploner,et al.(2006)."Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis:a cohort study." BMC Med 4:16.
Hutter,G.,M.Scheubner,et al.(2006)."Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors[p16(INK4a),p15(INK4b),p14(ARF)]in mantle cell lymphoma." Genes Chromosomes Cancer 45(2):203-10.
Jones,P.A.and S.M.Taylor(1980)."Cellular differentiation,cytidine analogs and DNA methylation." Cell 20(1):85-93.
Kerlikowske,K.,D.Grady,et al.(1996)."Likelihood ratios for modern screening mammography.Risk of breast cancer based on age and mammographic interpretation." Jama 276(1):39-43.
Kleer,C.G.,Q.Cao,et al.(2003)."EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells." Proc Natl Acad Sci U S A 100(20):11606-11.
Kriege,M.,C.T.Brekelmans,et al.(2004)."Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition." N Engl J Med 351(5):427-37.
Li,Y.,H.Nagai,et al.(2002)."Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype." Blood 100(7):2572-7.
Marks,P.A.,V.M.Richon,et al.(2004)."Histone deacetylase inhibitors." Adv Cancer Res 91:137-68.
Matsukawa,Y.,S.Semba,et al.(2006)."Expression of the enhancer of zeste homolog 2is correlated with poor prognosis in human gastric cancer." Cancer Sci 97(6):484-91.
McGarvey,K.M.,J.A.Fahrner,et al.(2006)."Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state." Cancer Res 66(7):3541-9.
McGarvey,K.M.,E.Greene,et al.(2007)."DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2." Cancer Res 67(11):5097-102.
Medh,R.D.,A.Wang,et al.(2001)."Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells." Oncogene 20(34):4629-39.
Mikkelsen,T.S.,M.Ku,et al.(2007)."Genome-wide maps of chromatin state in pluripotent and lineage-committed cells." Nature 448(7153):553-60.
Miller,A.B.,T.To,et al.(2002)."The Canadian National Breast Screening Study-1:breast cancer mortality after 11 to 16 years of follow-up.A randomized screening trial of mammography in women age 40 to 49 years." Ann Intern Med 137(5 Part 1):305-12.
Miller,L.D.,J.Smeds,et al.(2005)."An expression signature for p53 status in human breast cancer predicts mutation status,transcriptional effects,and patient survival." Proc Natl Acad Sci U S A 102(38):13550-5.
Nystrom,L.,I.Andersson,et al.(2002)."Long-term effects of mammography screening:updated overview of the Swedish randomised trials." Lancet 359(9310):909-19.
Ohm,J.E.,K.M.McGarvey,et al.(2007)."A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing." Nat Genet 39(2):237-42.
Ooi,S.K.,C.Qiu,et al.(2007)."DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA." Nature 448(7154):714-7.
Pan,G.(2007)."Whole-Genome Analysis of Histone H3 Lysine 4 and Lysine 27Methylation in Human Embryonic Stem Cells." Cell Stem Cell 1:299-312.
Pateras,I.S.,K.Apostolopoulou,et al.(2006)."Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer." Int J Cancer 119(11):2546-56.
Pei,X.H.,F.Bai,et al.(2007)."p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers." Cancer Res 67(7):3162-70.
Rosenberg,R.D.,W.C.Hunt,et al.(1998)."Effects of age,breast density,ethnicity,and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis:review of 183,134 screening mammograms in Albuquerque,New Mexico." Radiology 209(2):511-8.
Sanchez-Aguilera,A.,J.Delgado,et al.(2004)."Silencing of the p 18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas."Blood 103(6):2351-7.
Schlesinger,Y.,R.Straussman,et al.(2007)."Polycomb-mediated methylation on Lys27of histone H3 pre-marks genes for de novo methylation in cancer." Nat Genet 39(2):232-6.
Shames,D.S.,L.Girard,et al.(2006)."A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies."PLoS Med 3(12):e486.
Soejima,H.,T.Nakagawachi,et al.(2004)."Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer." Oncogene 23(25):4380-8.
Tan,J.,X.Yang,et al.(2007)."Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells." Genes Dev 21(9):1050-63.
Varambally,S.,S.M.Dhanasekaran,et al.(2002)."The polycomb group protein EZH2 is involved in progression of prostate cancer." Nature 419(6907):624-9.
Vire,E.,C.Brenner,et al.(2006)."The Polycomb group protein EZH2 directly controls DNA methylation." Nature 439(7078):871-4.
Weber,M.,I.Hellmann,et al.(2007)."Distribution,silencing potential and evolutionary impact of promoter DNA methylation in the human genome." Nat Genet 39(4):457-66.
Widschwendter,M.,H.Fiegl,et al.(2007)."Epigenetic stem cell signature in cancer."Nat Genet 39(2):157-8.
Wozniak,R.J.,W.T.Klimecki,et al.(2007)."5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation." Oncogene 26(1):77-90.
Yu,J.,D.R.Rhodes,et al.(2007)."A polycomb repression signature in metastatic prostate cancer predicts cancer outcome." Cancer Res 67(22):10657-63.
Zahl,P.H.,B.H.Strand,et al.(2004)."Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening:prospective cohort study."Bmj 328(7445):921-4.
Zhao,X.D.(2007)."Whole-Genome Mapping of Histone H3Lys4and27 Trimethylations Reveals Distinct Genomic Compartments in Human Embryonic Stem Cells." Cell Stem Cell 1:286-298.
Agger,K.,P.A.Cloos,et al.(2007)."UTX and JMJD3 are histone H3K27demethylases involved in HOX gene regulation and development." Nature 449(7163):731-4.
Ahn,M.Y.,J.H.Jung,et al.(2008)."A natural histone deacetylase inhibitor,Psammaplin A,induces cell cycle arrest and apoptosis in human endometrial cancer cells." Gynecol Oncol 108(1):27-33.
Al-Hajj,M.,M.S.Wicha,et al.(2003)."Prospective identification of tumorigenic breast cancer cells." Proc Natl Acad Sci U S A 100(7):3983-8.
Allfrey,V.G.,R.Faulkner,et al.(1964)."Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis." Proc Natl Acad Sci U S A 51:786-94.
Arce,C.,B.Segura-Pacheco,et al.(2006)."Hydralazine target:from blood vessels to the epigenome." J Transl Med 4:10.
Bachman,K.E.,B.H.Park,et al.(2003)."Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene." Cancer Cell 3(1):89-95.
Ballestar,E.and M.Esteller(2005)."Methyl-CpG-binding proteins in cancer:blaming the DNA methylation messenger." Biochem Cell Biol 83(3):374-84.
Bannister,A.J.and T.Kouzarides(1996)."The CBP co-activator is a histone acetyltransferase." Nature 384(6610):641-3.
Barski,A.,S.Cuddapah,et al.(2007)."High-resolution profiling of histone methylations in the human genome." Cell 129(4):823-37.
Baylin,S.B.and J.E.Ohm(2006)."Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?" Nat Rev Cancer 6(2):107-16.
Beach,R.,A.O.Chan,et al.(2005)."BRAF mutations in aberrant crypt foci and hyperplastic polyposis." Am J Pathol 166(4):1069-75.
Belinsky,S.A.,K.J.Nikula,et al.(1998)."Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis." Proc Natl Acad Sci U S A 95(20):11891-6.
Benbrahim-Tallaa,L.,R.A.Waterland,et al.(2007)."Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase." Environ Health Perspect 115(10):1454-9.
Berletch,J.B.,C.Liu,et al.(2008)."Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG." J Cell Biochem 103(2):509-19.
Bernstein,B.E.,T.S.Mikkelsen,et al.(2006)."A bivalent chromatin structure marks key developmental genes in embryonic stem cells." Cell 125(2):315-26.
Bernstein,E.and C.D.Allis(2005)."RNA meets chromatin." Genes Dev 19(14):1635-55.
Bird,A.(2002)."DNA methylation patterns and epigenetic memory." Genes Dev 16(1):6-21.
Bird,A.P.(1986)."CpG-rich islands and the function of DNA methylation."Nature 321(6067):209-13.
Bolden,J.E.,M.J.Peart,et al.(2006)."Anticancer activities of histone deacetylase inhibitors." Nat Rev Drug Discov 5(9):769-84.
Bourc'his,D.and T.H.Bestor(2004)."Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L."Nature 431(7004):96-9.
Bourc'his,D.,G.L.Xu,et al.(2001)."Dnmt3L and the establishment of maternal genomic imprints." Science 294(5551):2536-9.
Boyer,L.A.,K.Plath,et al.(2006)."Polycomb complexes repress developmental regulators in murine embryonic stem cells." Nature 441(7091):349-53.
Brena,R.M.and J.F.Costello(2007)."Genome-epigenome interactions in cancer." Hum Mol Genet 16 Spec No 1:R96-105.
Brownell,J.E.and C.D.Allis(1995)."An activity gel assay detects a single,catalytically active histone acetyltransferase subunit in Tetrahymena macronuclei." Proc Natl Acad SciUSA92(14):6364-8.
Brueckner,B.,R.G.Boy,et al.(2005)."Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases."Cancer Res 65(14):6305-11.
Brueckner,B.,C.Stresemann,et al.(2007)."The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function." Cancer Res 67(4):1419-23.
Cairns,P.(2007)."Gene methylation and early detection of genitourinary cancer:the road ahead." Nat Rev Cancer 7(7):531-43.
Candido,E.P.,R.Reeves,et al.(1978)."Sodium butyrate inhibits histone deacetylation in cultured cells." Cell 14(1):105-13.
Cao,R.,L.Wang,et al.(2002)."Role of histone H3 lysine 27 methylation in Polycomb-group silencing." Science 298(5595):1039-43.
Cao,R.and Y.Zhang(2004)."The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3." Curr Opin Genet Dev 14(2):155-64.
Cheng,J.C.,C.B.Matsen,et al.(2003)."Inhibition of DNA methylation and reactivation of silenced genes by zebularine."J Natl Cancer Inst 95(5):399-409.
Constantinides,P.G.,P.A.Jones,et al.(1977)."Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment." Nature 267(5609):364-6.
Cuthbert,G.L.,S.Daujat,et al.(2004)."Histone deimination antagonizes arginine methylation." Cell 118(5):545-53.
Dalerba,P.,R.W.Cho,et al.(2007)."Cancer stem cells:models and concepts."Annu Rev Med 58:267-84.
Dalerba,P.,C.Maccalli,et al.(2003)."Immunology and immunotherapy of colorectal cancer." Crit Rev Oncol Hematol 46(1):33-57.
Dancey,J.E.and H.X.Chen(2006)."Strategies for optimizing combinations of molecularly targeted anticancer agents." Nat Rev Drug Discov 5(8):649-59.
de la Cruz-Hemandez,E.,E.Perez-Cardenas,et al.(2007)."The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer,an in vitro and clinical study." Virol J 4:18.
De Santa,F.,M.G.Totaro,et al.(2007)."The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing." Cell 130(6):1083-94.
Dellino,G.I.,Y.B.Schwartz,et al.(2004)."Polycomb silencing blocks transcription initiation." Mol Cell 13(6):887-93.
Duan,H.,C.A.Heckman,et al.(2005)."Histone deacetylase inhibitors downregulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas." Mol Cell Biol 25(5):1608-19.
Egger,G.,G.Liang,et al.(2004)."Epigenetics in human disease and prospects for epigenetic therapy." Nature 429(6990):457-63.
Espada,J.and M.Esteller(2007)."Epigenetic control of nuclear architecture." Cell Mol Life Sci 64(4):449-57.
Esteller,M.(2007)."Cancer epigenomics:DNA methylomes and histonemodification maps." Nat Rev Genet 8(4):286-98.
Fabbri,M.,R.Garzon,et al.(2007)."MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B." Proc Natl Acad Sci U S A 104(40):15805-10.
Fahrner,J.A.,S.Eguchi,et al.(2002),"Dependence of histone modifications and gene expression on DNA hypermethylation in cancer." Cancer Res 62(24):7213-8.
Fearon,E.R.and B.Vogelstein(1990)."A genetic model for colorectal tumorigenesis." Cell 61(5):759-67.
Feinberg,A.P.(2007)."Phenotypic plasticity and the epigenetics of human disease." Nature 447(7143):433-40.
Feinberg,A.P.and B.Tycko(2004)."The history of cancer epigenetics." Nat Rev Cancer 4(2):143-53.
Feinberg,A.P.and B.Vogelstein(1983)."Hypomethylation distinguishes genes of some human cancers from their normal counterparts." Nature 301(5895):89-92.
Fraga,M.F.,E.Ballestar,et al.(2005)."Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer." Nat Genet 37(4):391-400.
Francis,N.J.and R.E.Kingston(2001)."Mechanisms of transcriptional memory."Nat Rev Mol Cell Biol 2(6):409-21.
Gal-Yam,E.N.,Y.Saito,et al.(2007)."Cancer Epigenetics:Modifications,Screening,and Therapy." Annu Rev Med.
Gershey,E.L.,G.Vidali,et al.(1968)."Chemical studies of historic acetylation.The occurrence of epsilon-N-acetyllysine in the f2al histone." J Biol Chem 243(19):5018-22.
Gifford,G.,J.Paul,et al.(2004)."The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients."Clin Cancer Res 10(13):4420-6.
Glaser,K.B.(2007)."HDAC inhibitors:Clinical update and mechanism-based potential." Biochem Pharmacol 74(5):659-71.
Glozak,M.A.and E.Seto(2007)."Histone deacetylases and cancer." Oncogene 26(37):5420-32.
Gonzalez-Zulueta,M.,C.M.Bender,et al.(1995)."Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing." Cancer Res 55(20):4531-5.
Gowher,H.and A.Jeltsch(2004)."Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy." Cancer Biol Ther 3(11):1062-8.
Greger,V.,E.Passarge,et al.(1989)."Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma." Hum Genet 83(2):155-8.
Gregoretti,I.V.,Y.M.Lee,et al.(2004)."Molecular evolution of the histone deacetylase family:functional implications of phylogenetic analysis." J Mol Biol 338(1):17-31.
Guan,Y.,B.Gerhard,et al.(2003)."Detection,isolation,and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)." Blood 101(8):3142-9.
Guzman,M.L.,C.F.Swiderski,et al.(2002)."Preferential induction of apoptosis for primary human leukemic stem cells." Proc Natl Acad Sci U S A 99(25):16220-5.
Hanahan,D.and R.A.Weinberg(2000)."The hallmarks of cancer." Cell 100(1):57-70.
Hassa,P.O.,S.S.Haenni,et al.(2006)."Nuclear ADP-ribosylation reactions in mammalian cells:where are we today and where are we going?" Microbiol Mol Biol Rev 70(3):789-829.
Hazzalin,C.A.and L.C.Mahadevan(2005)."Dynamic acetylation of all lysine 4-methylated histone H3 in the mouse nucleus:analysis at c-fos and c-jun." PLoS Biol 3(12):e393.
Hinshelwood,R.A.,L.I.Huschtscha,et al.(2007)."Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis." Cancer Res 67(24):11517-27.
Hitchins,M.P.,V.A.Lin,et al.(2007)."Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer." Cancer Res 67(19):9107-16.
Holleran,J.L.,R.A.Parise,et al.(2005)."Plasma pharmacokinetics,oral bioavailability,and interspecies scaling of the DNA methyltransferase inhibitor,zebularine." Clin Cancer Res 11(10):3862-8.
Issa,J.P.(2004)."CpG island methylator phenotype in cancer." Nat Rev Cancer 4(12):988-93.
Issa,J.P.and H.Kantarjian(2005)."Azacitidine." Nat Rev Drug Discov Suppl:S6-7.
Issa,J.P.,H.M.Kantarjian,et al.(2005)."Azacitidine." Nat Rev Drug Discov 4(4):275-6.
Jeltsch,A.(2006)."Molecular enzymology of mammalian DNA methyltransferases." Curr Top Microbiol Immunol 301:203-25.
Jia,D.,R.Z.Jurkowska,et al.(2007)."Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation." Nature 449(7159):248-51.
Jones,P.A.and S.B.Baylin(2002)."The fundamental role of epigenetic events in cancer." Nat Rev Genet 3(6):415-28.
Jones,P.A.and S.B.Baylin(2007)."The epigenomics of cancer." Cell 128(4):683-92.
Jones,P.A.and P.W.Laird(1999)."Cancer epigenetics comes of age." Nat Genet 21(2):163-7.
Joseph,J.,G.Mudduluru,et al.(2004)."Expression profiling of sodium butyrate (NaB)-treated cells:identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB." Oncogene 23(37):6304-15.
Kane,M.F.,M.Loda,et al.(1997)."Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines." Cancer Res 57(5):808-11.
Kaneda,A.and A.P.Feinberg(2005)."Loss of imprinting of IGF2:a common epigenetic modifier of intestinal tumor risk." Cancer Res 65(24):11236-40.
Kaneda,M.,M.Okano,et al.(2004)."Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting." Nature 429(6994):900-3.
Kantarjian,H.,J.P.Issa,et al.(2006)."Decitabine improves patient outcomes in myelodysplastic syndromes:results of a phase Ⅲ randomized study." Cancer 106(8):1794-803.
Kantarjian,H.,Y.Oki,et al.(2007)."Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia." Blood 109(1):52-7.
Kavi,H.H.,H.R.Fernandez,et al.(2005)."RNA silencing in Drosophila." FEBS Lett 579(26):5940-9.
Kawasaki,H.and K.Taira(2004)."Induction of DNA methylation and gene silencing by short interfering RNAs in human cells." Nature 431(7005):211-7.
Kennison,J.A.(1995)."The Polycomb and trithorax group proteins of Drosophila:trans-regulators of homeotic gene function." Annu Rev Genet 29:289-303.
Kennison,J.A.(2004)."Introduction to Trx-G and Pc-G genes." Methods Enzymol 377:61-70.
Kleff,S.,E.D.Andrulis,et al.(1995)."Identification of a gene encoding a yeast historic H4 acetyltransferase." J Biol Chem 270(42):24674-7.
Klose,R.J.,E.M.Kallin,et al.(2006)."JmjC-domain-containing proteins and histone demethylation." Nat Rev Genet 7(9):715-27.
Klymenko,T.,B.Papp,et al.(2006)."A Polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysine-binding activities." Genes Dev 20(9):1110-22.
Kondo,Y.,L.Shen,et al.(2004)."Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation." Proc Natl Acad Sci U S A 101(19):7398-403.
Kouzarides,T.(2007)."Chromatin modifications and their function." Cell 128(4):693-705.
Kouzarides,T.(2007)."SnapShot:Histone-Modifying Enzymes." Cell 131(4):822.
Lan,F.,P.E.Bayliss,et al.(2007)."A histone H3 lysine 27 demethylase regulates animal posterior development." Nature 449(7163):689-94.
Lapidot,T.,C.Sirard,et al.(1994)."A cell initiating human acute myeloid leukaemia after transplantation into SCID mice." Nature 367(6464):645-8.
Lee,B.H.,S.Yeguasubramanian,et al.(2005)."Procainamide is a specific inhibitor of DNA methyltransferase 1." J Biol Chem 280(49):40749-56.
Lee,K.K.and J.L.Workman(2007)."Histone acetyltransferase complexes:one size doesn't fit all." Nat Rev Mol Cell Biol 8(4):284-95.
Lee,M.G.,R.Villa,et al.(2007)."Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination." Science 318(5849):447-50.
Lee,T.I.,R.G.Jenner,et al.(2006)."Control of developmental regulators by Polycomb in human embryonic stem cells." Cell 125(2):301-13.
Leonhardt,H.,A.W.Page,et al.(1992)."A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei." Cell 71(5):865-73.
Liang,G.,J.C.Lin,et al.(2004)."Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome." Proc Natl Acad Sci U S A 101(19):7357-62.
Liu,Y.,E.J.Oakeley,et al.(1998)."Multiple domains are involved in the targeting of the mouse DNA methyltransferase to the DNA replication foci." Nucleic Acids Res 26(4):1038-45.
Lujambio,A.,S.Ropero,et al.(2007)."Genetic unmasking of an epigenetically silenced microRNA in human cancer cells." Cancer Res 67(4):1424-9.
Mancini,D.N.,D.I.Rodenhiser,et al.(1998)."CpG methylation within the 5'regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site." Oncogene 16(9):1161-9.
Mattick,J.S.and I.V.Makunin(2006)."Non-coding RNA." Hum Mol Genet 15Spec No 1:R17-29.
McGarvey,K.M.,J.A.Fahrner,et al.(2006)."Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state."Cancer Res 66(7):3541-9.
Metivier,R.,G.Penot,et al.(2003)."Estrogen receptor-alpha directs ordered,cyclical,and combinatorial recruitment of cofactors on a natural target promoter." Cell 115(6):751-63.
Miao,F.and R.Natarajan(2005)."Mapping global histone methylation patterns in the coding regions of human genes." Mol Cell Biol 25(11):4650-61.
Michaelis,M.,U.R.Michaelis,et al.(2004)."Valproic acid inhibits angiogenesis in vitro and in vivo." Mol Pharmacol 65(3):520-7.
Mikkelsen,T.S.,M.Ku,et al.(2007)."Genome-wide maps of chromatin state in pluripotent and lineage-committed cells." Nature 448(7153):553-60.
Mimeault,M.,R.Hauke,et al.(2007)."Recent advances in cancer stem/progenitor cell research:therapeutic implications for overcoming resistance to the most aggressive cancers." J Cell Mol Med 11(5):981-1011.
Moiseeva,E.P.,G.M.Almeida,et al.(2007)."Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression,reduced growth,and apoptosis of cancer cells." Mol Cancer Ther 6(11):3071-9.
Morris,K.V.,S.W.Chan,et al.(2004)."Small interfering RNA-induced transcriptional gene silencing in human cells." Science 305(5688):1289-92.
Morrison,S.J.and I.L.Weissman(1994)."The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype." Immunity 1(8):661-73.
Nathan,D.,K.Ingvarsdottir,et al.(2006)."Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications." Genes Dev 20(8):966-76.
Nebbioso,A.,N.Clarke,et al.(2005)."Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells." Nat Med 11(1):77-84.
Nelson,C.J.,H.Santos-Rosa,et al.(2006)."Proline isomerization of histone H3regulates lysine methylation and gene expression." Cell 126(5):905-16.
Nguyen,C.T.,D.J.Weisenberger,et al.(2002)."Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine."Cancer Res 62(22):6456-61.
Nightingale,K.P.,L.P.O'Neill,et al.(2006)."Histone modifications:signalling receptors and potential elements of a heritable epigenetic code." Curr Opin Genet Dev 16(2):125-36.
Nowak,S.J.and V.G.Corces(2004)."Phosphorylation of histone H3:a balancing act between chromosome condensation and transcriptional activation." Trends Genet 20(4):214-20.
Nowell,P.C.(1989)."The clonal nature of neoplasia." Cancer Cells 1(1):29-30.
Nuovo,G.J.,T.W.Plaia,et al.(1999)."In situ detection of the hypermethylationinduced inactivation of the p16 gene as an early event in oncogenesis." Proc Natl Acad Sci U S A 96(22):12754-9.
Ohm,J.E.,K.M.McGarvey,et al.(2007)."A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing."Nat Genet 39(2):237-42.
Okano,M.,D.W.Bell,et al.(1999)."DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development." Cell 99(3):247-57.
Ooi,S.K.,C.Qiu,et al.(2007)."DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA." Nature 448(7154):714-7.
Ozdag,H.,A.E.Teschendorff,et al.(2006)."Differential expression of selected histone modifier genes in human solid cancers." BMC Genomics 7:90.
Peart,M.J.,G.K.Smyth,et al.(2005)."Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors." Proc Natl Acad Sci U S A 102(10):3697-702.
Phillips,D.M.(1963)."The presence of acetyl groups of histones." Biochem J 87:258-63.
Pina,I.C.,J.T.Gautschi,et al.(2003)."Psammaplins from the sponge Pseudoceratina purpurea:inhibition of both histone deacetylase and DNA methyltransferase." J Org Chem 68(10):3866-73.
Pirrotta,V.(1999)."Polycomb silencing and the maintenance of stable chromatin states." Results Probl Cell Differ 25:205-28.
Qiu,L.,A.Burgess,et al.(2000)."Histone deacetylase inhibitors trigger a G2checkpoint in normal cells that is defective in tumor cells." Mol Biol Cell 11(6):2069-83.
Rea,S.,F.Eisenhaber,et al.(2000)."Regulation of chromatin structure by sitespecific histone H3 methyltransferases." Nature 406(6796):593-9.
Reik,W.,W.Dean,et al.(2001)."Epigenetic reprogramming in mammalian development." Science 293(5532):1089-93.
Ricci-Vitiani,L.,D.G.Lombardi,et al.(2007)."Identification and expansion of human colon-cancer-initiating cells." Nature 445(7123):111-5.
Richon,V.M.,T.W.Sandhoff,et al.(2000)."Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation." Proc Natl Acad Sci U S A 97(18):10014-9.
Rocchi,P.,R.Tonelli,et al.(2005)."p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors(valproic acid,tributyrin and sodium butyrate) in neuroblastoma cells." Oncol Rep 13(6):1139-44.
Roh,T.Y.,S.Cuddapah,et al.(2006)."The genomic landscape of histone modifications in human T cells." Proc Natl Acad Sci U S A 103(43):15782-7.
Roh,T.Y.,W.C.Ngau,et al.(2004)."High-resolution genome-wide mapping of histone modifications." Nat Biotechnol 22(8):1013-6.
Ropero,S.,M.F.Fraga,et al.(2006)."A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition." Nat Genet 38(5):566-9.
Sakajiri,S.,T.Kumagai,et al.(2005)."Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines." Exp Hematol 33(1):53-61.
Santos-Rosa,H.,R.Schneider,et al.(2002)."Active genes are tri-methylated at K4of histone H3." Nature 419(6905):407-11.
Saurin,A.J.,Z.Shao,et al.(2001)."A Drosophila Polycomb group complex includes Zeste and dTAFII proteins." Nature 412(6847):655-60.
Schlesinger,Y.,R.Straussman,et al.(2007)."Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer." Nat Genet 39(2):232-6.
Seligson,D.B.,S.Horvath,et al.(2005)."Global histone modification patterns predict risk of prostate cancer recurrence." Nature 435(7046):1262-6.
Shi,Y.and J.R.Whetstine(2007)."Dynamic regulation of historic lysine methylation by demethylases." Mol Cell 25(1):1-14.
Shilatifard,A.(2006)."Chromatin modifications by methylation and ubiquitination:implications in the regulation of gene expression." Armu Rev Biochem 75:243-69.
Smallwood,A.,P.O.Esteve,et al.(2007)."Functional cooperation between HP1and DNMT1 mediates gene silencing." Genes Dev 21(10):1169-78.
Soriano,A.O.,H.Yang,et al.(2007)."Safety and clinical activity of the combination of 5-azacytidine,valproic acid,and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome." Blood 110(7):2302-8.
Sorm,F.,A.Piskala,et al.(1964)."5-Azacytidine,a new,highly effective cancerostatic." Experientia 20(4):202-3.
Sterner,D.E.and S.L.Berger(2000)."Acetylation of histones and transcriptionrelated factors." Microbiol Mol Biol Rev 64(2):435-59.
Suzuki,H.,E.Gabrielson,et al.(2002)."A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer." Nat Genet 31(2):141-9.
Ting,A.H.,K.M.McGarvey,et al.(2006)."The cancer epigenome—components and functional correlates." Genes Dev 20(23):3215-31.
Toyoda,A.,H.Noguchi,et al.(2002)."Comparative genomic sequence analysis of the human chromosome 21 Down syndrome critical region." Genome Res 12(9):1323-32.
Turner,B.M.(2007)."Defining an epigenetic code." Nat Cell Biol 9(1):2-6.
van Leenders,G.J.,D.Dukers,et al.(2007)."Polycomb-group oncogenes EZH2,BMI1,and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features." Eur Urol 52(2):455-63.
Varambally,S.,S.M.Dhanasekaran,et al.(2002)."The polycomb group protein EZH2 is involved in progression of prostate cancer." Nature 419(6907):624-9.
Venturelli,S.,S.Armeanu,et al.(2007)."Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma." Cancer 109(10):2132-41.
Vire,E.,C.Brenner,et al.(2006)."The Polycomb group protein EZH2 directly controls DNA methylation." Nature 439(7078):871-4.
Volkel,P.and P.O.Angrand(2007)."The control of histone lysine methylation in epigenetic regulation." Biochimie 89(1):1-20.
Wang,L.,J.L.Brown,et al.(2004)."Hierarchical recruitment of polycomb group silencing complexes." Mol Cell 14(5):637-46.
Weisenberger,D.J.,K.D.Siegmund,et al.(2006)."CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer." Nat Genet 38(7):787-93.
Wilson,A.S.,B.E.Power,et al.(2007)."DNA hypomethylation and human diseases." Biochim Biophys Acta 1775(1):138-62.
Wu,H.,Y.Chen,et al.(2005)."Hypomethylation-linked activation of PAX2mediates tamoxifen-stimulated endometrial carcinogenesis." Nature 438(7070):981-7.
Yamada,Y.,L.Jackson-Grusby,et al.(2005)."Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis." Proc Natl Acad Sci U S A 102(38):13580-5.
Yang,X.J.and E.Seto(2007)."HATs and HDACs:from structure,function and regulation to novel strategies for therapy and prevention." Oncogene 26(37):5310-8.
Yoo,C.B.and P.A.Jones(2006)."Epigenetic therapy of cancer:past,present and future." Nat Rev Drug Discov 5(1):37-50.
Yu,J.,Q.Cao,et al.(2007)."Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer." Cancer Cell 12(5):419-31.
Yu,J.,D.R.Rhodes,et al.(2007)."A polycomb repression signature in metastatic prostate cancer predicts cancer outcome." Cancer Res 67(22):10657-63.
Zambrano,P.,B.Segura-Pacheco,et al.(2005)."A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes." BMC Cancer 5(1):44.
Zhang,Y.and D.Reinberg(2001)."Transcription regulation by histone methylation:interplay between different covalent modifications of the core histone tails." Genes Dev 15(18):2343-60.
Zhao,Y.,J.Tan,et al.(2005)."Inhibitors of histone deacetylases target the RbE2F1pathway for apoptosis induction through activation of proapoptotic protein Bim."Proc Natl Acad Sci U S A 102(44):16090-5.